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ROLE OF TUMOR NECROSIS FACTOR-STIMULATED GENE-6 IN

CUTANEOUS WOUND HEALING AND INFLAMMATION

SAJINA SHAKYA
ABSTRACT
Controlled inflammation is crucial for normal wound healing. Our main aim

in this study was to investigate the effect of loss of tumor necrosis factor-stimulated
gene-6 (TSG-6) in cutaneous wound closure and inflammation. TSG-6 by its

enzymatic action modifies the extracellular matrix molecule, hyaluronan (HA),
through the transfer of heavy chain (HC) proteins from inter-a-trypsin inhibitor to
form HC-HA complexes. Both TSG-6 and HC-HA have been associated with

inflammation. Here, we showed that loss of endogenous TSG-6 and HC-HA in
TSG-6 null mice results in significantly delayed wound closure and differential

neutrophil recruitment compared to wildtype mice. Both of these phenotypes were

successfully rescued by reintroduction of TSG-6 into null wounds. We also
observed leukocyte recruitment behavior upon chemical injury and propose
interesting differences between wildtype and TSG-6 null animals. Further, we

showed that levels of the pro-inflammatory cytokine TNFa, and the presence of
M1 proinflammatory macrophages, were elevated in TSG-6 null wounds compared

to wildtype wounds. To facilitate the analysis of wound macrophages, we have

described a detailed protocol to isolate single cells from cutaneous wounds. In a
nutshell, our study indicates that TSG-6 is required for normal wound closure and
plays an important role in regulating inflammation during wound repair.
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CHAPTER I
I.

1.1

INTRODUCTION

Overview

A wound in simplest terms is any kind of disruption, shallow or deep, of the
protective epithelial barrier of the skin. The most common causes of wounds are
trauma or accidents, including burns, surgical intervention due to various

underlying conditions, and ulcers due to long-term pressure, shear, or chronic
diseases such as diabetes and vascular insufficiency. Depending upon the length

of time required for healing, wounds are basically categorized as either acute or
chronic. While acute wounds heal normally, chronic wounds are the kind that do

not heal and remain open for more than one month (Lindholm and Searle 2016;

Sen 2019).
Chronic wounds generally do not occur in healthy individuals, and are
instead connected to some underlying pathological condition such as diabetes or

cardiovascular disease. Because of this, the cost of wound care management has
not been as well defined as other health conditions (Sen et al. 2009). However,

recently available studies show that management of wound care makes up a
substantial portion of the health care economies of the USA and Europe (the two
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largest wound-dressing markets in the world). Thus, an estimated 6.5 million

people in the USA and 2 million people in Europe are affected by chronic wounds
at any one time (Lindholm and Searle 2016; Sen 2019).

A retrospective analysis of the Medicare 5% Limited Data Set for 2014 by
Nussbaum et al. of different categories of acute and chronic wounds, published in
2018, found that ~15% of Medicare users, equating to 8.2 million people, had at

least one type of wound or infection. The most prevalent cause of wounds was
found to be surgical wounds at 4%, followed by diabetic infections at 3.4%. The
resultant total Medicare expense for all analyzed wounds was projected at

between $28.1 and $96.8 billion (Nussbaum et al. 2018). Considering that chronic
wounds are most common in the elderly and in people with underlying conditions

(such as diabetes), both populations that are on the rise, costs can be expected to
increase even more in the coming years. Overall, about 2% of the total U.S.

population is estimated to be affected by chronic wounds (Sen 2019).
Another retrospective cohort analysis of the Healthy Improvement Network

Database for wound management in the U.K. during 2012-2013 found that an
estimated 2.2 million wounds were treated during that time period, amounting to a
cost ranging from £4.5 to £5.1 billion. The most common wound type observed in

that population was leg ulcers (uncharacterized etiology) at 19%, followed by leg
ulcers (venous etiology) at 13% (Guest et al. 2015).

The costs of wound management include expenses related to wound care
products and devices, to hospital stays and outpatient hospital visits, and to fees
from health care professionals. Wounds also have a significant impact on the

2

quality of life, both for the injured person and for caregivers including family
members; the multiple stressors involving pain, anxiety, social isolation, and loss
of financial income. Due to the hidden effects of chronic wounds not only upon the
patient but also the people around them, the phenomenon pf non-healing wounds
has been called ‘the silent epidemic’ (Lindholm and Searle 2016).

1.2

Wound treatments, and our limited understanding of the biology of
wound healing

Depending upon the extent and type of the wound, wound healing involves
various types of cells including epidermal cells, inflammatory cells, endothelial cells

and connective tissue cells. Importantly proper wound healing requires the timely
and controlled activation of all cells and tissues involved. For successful wound

management, the main purpose is to attain fast wound closure while avoiding any
kind of infection while attaining the least scar possible (Martin 1997). Several

developments have been made in the field of wound healing to fulfill this purpose.
Some of these include wound dressings, surgical (grafts) and non-surgical

innovations, growth factors, and (most recently) stem cell therapy (Ather et al.
2019).
Wound dressings or bandages, along with topical ointments, are the

simplest category of wound healing methodology and has been in practice for a

long time. While the ancient Egyptians used honey-soaked linens as rather
effective antimicrobial wound dressings, newer developments have been made in

the field by introducing interactive dressings made of hydrophilic materials such as

hydrogels, alginates, polyurethane foams, and hydrocolloids which can retain
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moisture, thereby making a more favorable environment to improve wound

healing. Dressings made of semi-permeable films are now available, which are

permeable to water vapor and oxygen but not to water and infectious
microorganisms. (Ather et al. 2019; Dhivya et al. 2015). Bioengineered grafts and
tissue engineered skin substitutes including auto-, allo-, or xeno-grafts (epidermal

or dermal) are under investigation, designed to be surgically applied to the injured

area. Other, non-surgical methodologies such as negative pressure wound
therapy, hyperbaric oxygen,, and electrical stimulation to restore electrical
potential of the cells, are also available (Ather et al. 2019). Additionally, studies are

being conducted to understand the application of protein growth factors, such as
epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet derived

growth factors (PDGF), that were shown to promote wound healing in murine
models. Most recently, the use of stem cells that can release a number of these

growth factors is also being investigated (Ather et al. 2019; Yamakawa and
Hayashida 2019).

Unfortunately (and rather disappointingly), none of the above-mentioned
advancements in wound treatment methodologies have made a significant
difference in reducing current rates of morbidity and mortality in the setting of
chronic human wounds. The inescapable conclusion is that only be obtaining a
better understanding of the critical underlying biological events in the wound micro
environment, can we hope to achieve better wound healing outcomes. Conversely,

when armed with improved understanding of basic biology, there will be hope for
developing more efficient treatments for chronic wounds.
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1.3

TSG-6, an important protein that regulates the status of hyaluronan
in the extracellular matrix, the availability of cytokines, and the

course of inflammation during the course of wound repair.

Our purpose here is to understand the underlying biology of wound healing
with respect to the ubiquitous extracellular matrix hyaluronan (HA) which is known

to play important roles in wound healing (Maytin 2016). In this thesis we investigate
the role of tumor necrosis factor-stimulated gene-6 (TSG-6) protein during
cutaneous wound healing by employing a mouse model which lacks the gene that

encodes TSG-6. More details on these molecules and their roles in wound healing

are discussed in Chapters 2 and 3.
1.4

Specific Aims

Specific Aim 1: To determine how loss of TSG-6 affects wound closure and

recruitment of inflammatory cells. [Chapter 3]
Rationale: Faster wound closure is a prime goal in wound management, to

prevent infection and loss of body fluids. Literature suggests that TSG-6 plays an

anti-inflammatory role by inhibiting neutrophil recruitment and by promoting the
appearance of tissue-reparative macrophages. Also, studies show that exogenous

sources of TSG-6 promote faster wound closure. For these reasons, the absence

of TSG-6 in TSG-6 null mice are expected to make cutaneous wounds heal slower,
accompanied by exacerbated inflammation, when compared to wounds in wild

type (WT) mice.
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Hypotheses: (1) Absence of anti-inflammatory TSG-6 protein will cause a delay
in wound closure in TSG-6 null mice. (2) TSG-6 null mice will have increased
neutrophil recruitment and abnormal macrophage polarization. (3) Re-introduction
of TSG-6 to the null wounds by addition of recombinant TSG-6 will rescue both the
wound closure delay and the proinflammatory phenotype in TSG-6 null mice.

Specific Aim 2: To develop a viable protocol to isolate single cells from cutaneous

wounds for flow sorting and flow cytometric assessment of leukocytes in WT and
TSG-6 null wounds, with a particular emphasis on macrophages. [Chapter 4]

Rationale: Flow sorting and flow cytometric analysis are sensitive ways to analyze

individual cells or a certain population of cells. However, a detailed protocol to
isolate single cells from cutaneous wounds is lacking. Availability of a

comprehensive protocol, describing all the minute details of single leukocyte cell
isolation, will further the understanding of the wound microenvironment.

Hypothesis: (1) The flow-sorted population of wound macrophages will express
the macrophage-specific adhesion G protein-coupled receptor E1 (Adgre1) gene,

while the non-macrophage population will not express this gene. (2) Flow
cytometric analysis will allow us to analyze each cell in the single cell suspension
and help us determine the different levels of macrophage polarization.

Specific Aim 3: To determine how the absence of TSG-6 affects rolling and

adhesion behavior of leukocytes in vivo after chemical injury using intravital
microscopy. [Chapter 5]

6

Rationale: Literature indicates that TSG-6 plays an anti-inflammatory role by

inhibiting neutrophil recruitment. However, direct evidence regarding the details of
neutrophil transmigration behavior within small blood vessels at sites of injury in

the skin is missing. Intravital microscopy allows the assessment of leukocytes in
vivo, and therefore should make it possible to understand the effects that loss of
TSG-6 exerts upon leukocyte rolling and adhesion behavior.

Hypothesis: (1) Upon chemical injury, leukocyte rolling behavior in cutaneous

blood vessels in TSG-6 null mice will be differentially regulated as compared to

WT mice. (2) Upon chemical injury, leukocyte adhesion (arrest) behavior in the
blood vessels of TSG-6 null mice will be differentially regulated as compared to

WT mice.
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CHAPTER II
II.

BACKGROUND

The purpose of this chapter is to provide the reader with sufficient
background information to understand the following main concepts: (1) The

different stages of cutaneous wound healing; (2) the inflammatory cells involved in
wound healing, including how these cells get recruited to the wound site and what

roles they play; and (3) how tumor necrosis factor-stimulated gene-6 (TSG-6)
modifies hyaluronan (HA) and affects inflammation in the skin.

2.1

The Skin: A brief overview

The skin is a large organ that covers the entire body of an animal, forming
a physical barrier between the organism and its environment. The skin is

conventionally described as consisting of two layers- the outer epithelial tissue

layer (epidermis), and the inner connective tissue layer (dermis) (Figure 2-1).
Under the skin is a layer of adipose tissue called the subcutaneous layer, or
hypodermis (McLafferty et al. 2012; Odland and Goldsmith 1991).

The epidermis comprises several stratified layers of keratinizing epithelium,
which are named (from outermost to innermost) as the stratum corneum, the

stratum granulosum, the stratum spinosum, and the stratum basale. The major cell
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type of the epidermis is the keratinocyte. Keratinocytes in the basal layer are
cuboidal and are actively dividing. With maturation, these cuboidal cells

differentiate and undergo physical changes as they migrate upwards, forming the
upper layers of the epidermis. In addition to keratinocytes, other cell types are

dispersed within the different layers of the epidermis; these include melanocytes,
Langerhans cells, and Merkel cells, with each cell type performing specific
functions. Also embedded within the skin are various appendages, such as the
hair follicle, the sebaceous gland, and the sweat gland. These appendages are

vital for thermoregulation and environmental sensing. Thus, the skin forms a
protective, semi-permeable envelope that aids in the regulation of body
homeostasis (Proksch et al. 2008; Sotiropoulou and Blanpain 2012). Under the
epidermis is a layer of extracellular matrix known as the basement membrane that
separates the epidermis from the underlying dermis.

The dermis is a connective tissue layer composed of structural components,
such as collagen fibers (predominantly Types I and III), elastic fibers (elastin and

fibrillin), and glycosaminoglycans (GAGs, including hyaluronan) that provide

physical strength to the skin. The major cell type of the dermis is the fibroblast

which is primarily responsible for the maintenance of the structural elements of the
dermis. Other cell types in the dermis are resident dermal macrophages and

dendritic cells. The dermis also contains a network of vasculature, nerves, and the
appendages mentioned above. With the aid of all of these cellular and structural

components, the dermis provides mechanical strength and nutrients to the skin

(McLafferty et al. 2012; Odland and Goldsmith 1991).
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Epidermis

Dermis

Hypodermis
(subcutis)

Apocrine
sweat gland

Arrector pili Hair root Sebaceous Eccrine
muscle
gland sweat gland

Figure 2-1. Skin is conventionally divided into two layers.
The upper epithelial tissue layer called the epidermis provides a semi-permeable barrier, and
the lower connective tissue layer called the dermis provides mechanical strength. [Adapted
from (Rehfeld et al. 2017)]

2.2

Wound healing: General introduction

As the skin is the first layer of protection for the body against the outside
environment, the presence of an intact barrier layer is critical. Loss of integrity of

skin, for any reason, is termed as skin wound. Skin wounds can be caused by
accidents (trauma), burns, surgery, or as a result of chronic diseases such as

diabetes. Depending upon the level of injury and the time it takes to heal, wounds

can be grossly categorized as acute wounds or chronic wounds (Lindholm and
Searle 2016).
While the main goal of wound care management, in general, is to attain fast

and efficient wound closure with the least scar, not all wounds heal normally
(Martin 1997). Abnormal wound healing is an important medical issue (as

discussed in Chapter 1), whether the problem is a non-healing wound (chronic
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ulcer) or an imperfectly healing wound (e.g., hypertrophic scars or keloid). To

understand the many possible reasons for abnormal wound healing, a basic
understanding of normal wound healing biology is essential. The next section gives

a brief picture of this complex process.

2.2.1 Phases of cutaneous wound healing
Wound healing is an intricate affair, involving a timely and controlled action

of many different cell types and molecules. To better conceptualize this complex
process, the events in wound healing are divided into three major phases that
partially overlap in time. These steps are, a) the inflammatory phase, b) the tissue

formation phase, and c) the tissue remodeling phase. Figure 2-2 illustrates the
various events that occur during the three phases of wound healing, which are also

described briefly below.
2.2.1.1 Inflammatory phase

In the first part of the inflammatory phase, the injured endothelial cells
release signals that initiate vasoconstriction immediately after wounding.
Circulating platelets aggregate at the wound site, forming a physical plug (blood

clot) that helps to stop blood loss and achieve hemostasis. This platelet plug further
acts as a provisional matrix (a scaffold) for later events. Also, platelets release

essential growth factors, such as platelet-derived growth factor (PDGF) and

transforming growth factor (TGF-b), along with cytokines such as tumor necrosis
factor (TNF)-a and interleukin (IL) -1 that promote migration (chemotaxis) of

leukocytes and fibroblasts (Kirsner and Eaglstein 1993; Singer and Clark 1999).
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The next event in the inflammatory phase is the influx of inflammatory
leukocytes into the wound site following the release of the cytokines and growth

factors by the platelets and endothelial cells. Neutrophils are the first of the
leukocytes to reach the wound site, coming in as early as the first few hours (Clark
2001; Diegelmann and Evans 2004). These cells release proteases from their

cytotoxic granules that attack any infectious agents in the wound. The neutrophils
in normal wounds are short-lived and quickly undergo apoptosis. Following closely
behind, monocytes reach the site in about 2-3 days and differentiate into
macrophages which phagocytose the debris, including dead neutrophils and

bacteria (Broughton et al. 2006). Macrophages are further categorized into pro-

inflammatory M1 phenotypes and anti-inflammatory M2 phenotypes, which will be
discussed further in detail in a separate section below. Briefly, M1 macrophages

release the toxic agent nitric oxide, thus promoting inflammation, whereas M2
macrophages produce polyamines essential for cell functions (Martinez and

Gordon 2014). Activated leukocytes also release several inflammatory cytokines,

continuing the cascade of events.
2.2.1.2 Tissue formation phase

The second phase in wound healing is the tissue formation phase, which
starts around 3 days after injury and continues for about a week. It is characterized
by epithelial migration and proliferation, along with fibroblast migration,
proliferation and differentiation. In this phase, cross-talk (between macrophages

and fibroblasts primarily) initiate fibroblast proliferation; migration of keratinocytes
occurs; and synthesis of collagens and GAGs by activated fibroblasts begins.
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Additionally, keratinocytes express VEGF, resulting in the proliferation of

endothelial cells and the formation of new vessels, termed as neovascularization.

Collectively, this newly formed tissue is called granulation tissue, so-called
because

of the

granular

appearance

of the

small

hemorrhagic

dots

(neovascularization) that are visible when a newly-forming scab is picked off the

skin (Broughton et al. 2006; Diegelmann and Evans 2004; Kirsner and Eaglstein
1993).

2.2.1.3 Tissue remodeling phase
The tissue remodeling phase starts at about the first week after injury.

During this last phase of wound healing, the fibroblasts phenotypically differentiate
into myofibroblasts.

Myofibroblasts are activated fibroblasts that contain

microfilaments of alpha smooth muscle actin (a-SMA) which enable them to

contract. Thus, wound contraction is made possible by fibroblast-to-myofibroblast

conversion. Additionally, the deposition of extracellular matrix (ECM) continues
and eventually replaces the granulation tissue with a mature and organized matrix
rich in collagen. Inflammation gradually resolves, and the newly formed vessels
start to retract (Olczyk et al. 2014; Schafer and Werner 2008). The tissue

remodeling phase can continue from weeks to months.

Hyaluronan (HA) is an important extracellular matrix molecule in skin that is
known to play important roles in all different phases of wound healing (Figure 2-2).
HA is known to facilitate neutrophil infiltration into the wound site, to maintain
vascular integrity by modifying the endothelial glycocalyx, to modify epithelial

migration, to affect the expression of pro-inflammatory cytokines like TNFa, and to
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regulate angiogenesis (Aya and Stern 2014). More about HA will be discussed in
Section 2.3 below.

Figure 2-2. Wound healing is a complex process.
Depicted are the sequence of events during normal cutaneous wound healing. Each of the
three phases- (a) inflammation, (b) tissue formation, and (c) remodeling, consists of multiple
events happening simultaneously. [Adapted from (Gurtner et al. 2008)

2.2.2

Inflammatory cells in wound healing

2.2.2.1 Recruitment of inflammatory leukocytes

A large part of this Thesis revolves around the second part of the
inflammatory phase of wound healing, i.e. the recruitment of inflammatory
leukocytes into wounds, specifically neutrophils and macrophages. Inflammatory
cells are not normally present outside the blood vessels in normal skin, but after
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injury, leukocytes invade the extravascular tissue in large numbers in response to

different cytokines and chemokines. Leukocyte export is facilitated by different
chemotactic factors and their interaction with the endothelial cells (Diegelmann and
Evans 2004). Different cytokines and chemokines produced by injured tissue cell
types, including endothelial cells and the macrophages and activated neutrophils

themselves, facilitate the recruitment of leukocytes from the circulating blood.
Once out of the vessels, leukocytes are stimulated to act as phagocytic cells and/or

release their contents, causing cytotoxic effects. Recruitment of circulating
leukocytes from the blood circulation to the injury site entails multiple steps (Figure

2-3), and involves the sequential activation of different adhesion molecules and
their corresponding ligands on leukocytes and endothelial cells (Wagner and Roth
2000). The specificity of leukocyte migration is mostly determined by the type of

adhesion molecules expressed.

Events in Leukocyte extravasation:
The first step in the migration of leukocytes is capture/tethering and rolling
(Ley et al. 2007), which is mediated by a kind of transmembrane glycoprotein

adhesive molecule called selectin. Three different types of selectins are
responsible for this process, causing the leukocytes to slowly roll on the vessel
wall. When suitable inflammatory stimuli are present, P-selectins on platelets and

endothelial cells can efficiently capture neutrophils from the flow by binding to their

ligands on the neutrophils (Stone and Nash 1999). The next selectin type is Lselectin which is present on the surface of leukocytes and binds to its ligand on
endothelial cells (Kishimoto et al. 1995). The third type of selectin, E-selectin, is
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expressed on endothelial cells upon stimulation by inflammatory cytokines, and
binds to its ligand on the surface of neutrophils. Selectin-induced binding of

neutrophils to the endothelial cells is a weak and reversible interaction. Binding
decreases the velocity of the blood cells and helps in margination. A firmer type of

binding, known as adhesion, needs to occur before leukocytes can transmigrate

from the circulation (Ley et al. 2007).

The next step in the migration of leukocytes is adhesion, in which leukocytes
adhere more strongly to the vessel wall. The process is mediated by two groups

of molecules, namely, integrins and cellular adhesion molecules (CAMs). Integrins

are glycoproteins on migrating cells, that play an important role in intercellular
binding as well as in mediating interactions between migrating cells and the
extracellular tissue (Von Andrian et al. 1992; Wagner and Roth 2000). The second

group of adhesion molecules, CAMs, such as intercellular adhesion molecule
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), act as ligands on the
endothelial cells for the integrin molecules (Sadik et al. 2011). These adhesion

molecules are activated by different inflammatory cytokines such as tumor

necrosis factor (TNF)- a and interleukin-1 (IL-1), as well as the selectin-mediated
interaction between leukocytes and endothelial cells (Lawrence and Springer
1991; Reinhardt et al. 1997; Von Andrian et al. 1992; Wagner and Roth 2000).

Once activated, the integrin-mediated cell-cell interaction is strong and stable. With
time, as more signals are received, more integrin-ligand binding occurs. This

causes a stronger and more stable binding between the two types of cells,

preparing leukocytes to escape from the blood vessels.
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Adhesion is then followed by diapedesis or transmigration. This is the
movement of leukocytes through the endothelial cell layer by either transcellular or
paracellular migration.

Numerous cytokines and chemotactic factors are

responsible for this. One of the major mediators of trans-endothelial migration is
Platelet/endothelial cell adhesion molecule 1 (PECAM-1 or CD31). It was shown

that when PECAM-1 was blocked using anti-PECAM, transmigration of neutrophils
was inhibited (Muller et al. 1993; Wagner and Roth 2000).

Figure 2-3. The extravasation of leukocytes involves a cascade of events.
Upon receiving chemical signals from the wound bed, the freely flowing leukocytes in the blood
vessels start slowing down, roll on the endothelium, adhere, and finally transmigrate. [Adapted
from (Ley et al. 2007)]

2.2.2.2 Functions of inflammatory leukocytes in cutaneous wound healing

and repair
Neutrophils, also known as polymorphonuclear leukocytes (PMNs), are the

first circulating inflammatory cells to be recruited to the wound bed after injury.
Recruitment of neutrophils starts within a few minutes after injury, mediated by

chemokines such as IL-8 and monocyte chemoattractant protein-1 (MCP-1)
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(Engelhardt et al. 1998). Figure 2-4 below depicts the functions of neutrophils in
wound healing and repair.

Figure 2-4. Neutrophils play important roles in wound healing and tissue repair.
Neutrophils are the first inflammatory cells to get to the injury site and play critical roles in
proper wound healing and repair. [Adapted from (Wang 2018)]

The recruited neutrophils remove necrotic cells and phagocytose any
foreign/infectious agents in the injured tissue by releasing active antimicrobial

substances, such as reactive oxygen species (e.g., nitric oxide and hydrogen

peroxide), cationic peptides, and proteases such as elastase and proteinases. This
is critical for preventing any possible infection, as delayed neutrophil recruitment
has been associated with compromised wound healing in humans as well as mice

(Eming et al. 2007; Hampton et al. 1998; Nishio et al. 2008; Wang 2018). Another

important role of neutrophils is the production of cytokines that activate
macrophages and augment inflammatory response. After performing these
functions, the recruited neutrophils die (become apoptotic) and are removed by

macrophages. Those macrophages also release a variety of growth factors and
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anti-inflammatory cytokines. The timely removal of neutrophils is critical, since the

toxic factors that neutrophils secrete (although useful for removing infectious

agents) can also harm host tissues. Thus, prolonged neutrophil recruitment is
linked to impaired wound healing and chronic inflammation (Hampton et al. 1998;
de Oliveira et al. 2016; Smith 1994; Wang 2018).

Monocytes are the next group of inflammatory cells recruited from the

circulation. The monocytes mature and differentiate into macrophages once they

complete their transmigration through the endothelium. Macrophage recruitment
in the wound bed is mediated by different chemotactic growth factors and

cytokines, including chemokines such as macrophage inflammatory protein (MIP)

1a, MCP-1, and RANTES (Eming et al. 2009). Macrophages first appear around
2-3 days post injury and phagocytose the apoptotic neutrophils. They also
contribute to matrix reformation and remodeling by secreting various growth

factors and by activating fibroblasts and supporting angiogenesis (Figure 2-5).
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Figure 2-5. Macrophages perform several functions in cutaneous wound healing.
The second type of inflammatory cells, macrophages, appear around 2 days post injury and
last for weeks, playing important roles in different events of wound healing. [Adapted from
(Chhabra et al. 2017)]
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Wound macrophages (F) are broadly categorized, based upon their
activation stimuli, the markers they express, and the functions they perform, into

two phenotypes, These are the classically activated/ pro-inflammatory M1
macrophages, and the alternatively activated/ anti-inflammatory M2 macrophages,
also called as tissue reparative macrophages (Figure 2-6) (Hesketh et al. 2017a).

Polarization (differentiation) of macrophage into the M1 phenotype is mediated by
pro-inflammatory factors such as interferon (IFN)-g, TNF-a, lipopolysaccharide

(LPS), and damage associated pattern molecules (DAMPs). In turn, M1
macrophages produce a myriad of pro-inflammatory cytokines, chemokines, and

other mediators including TNF-a, IL-6, IL-1b, IL-12, chemokine [C-X-C motif] ligand

10 (CXCL10), CXCL11, and inducible nitric oxide synthase (iNOS), thus promoting
inflammation. M1

macrophages normally appear in the early stages of

inflammation and are characterized by the expression of these pro-inflammatory

markers (High levels of iNOS, TNFa, IL-12, and IL-6; Low levels of IL-10). On the
other hand, M2 macrophage activation (also called ‘alternative activation’) is

mediated by anti-inflammatory cytokines and factors such as, IL-4, IL-10, IL-13,
and glucocorticoids. M2 macrophages secrete anti-inflammatory cytokines and

growth factors such as, IL-10, transforming growth factor (TGF)-b, VEGF, and
insulin-like growth factor-1. The M2 macrophages are responsible for the
phagocytosis of apoptotic neutrophils, and execution of tissue reparative functions.

Common markers used to identify M2 macrophages are high levels of Arginase-1
and IL-10, along with low levels of TNF-a and IL-12 (Hesketh et al. 2017a; Koh
and DiPietro 2011; Martinez and Gordon 2014).

20

An important thing to note here is that the M1 and M2 phenotypes do not

exactly represent two distinct cell populations. Instead, the idea of M1/M2
represents a range of population characteristics that depends upon the
macrophage microenvironment, and the maturation of macrophages according to

the available stimulation (Brancato and Albina 2011; Koh and DiPietro 2011).

Secrete
Anti-inflammatory cytokines
(e.g. IL-10, IL-1RII, IL-IRA)
Chemokines
(e.g. CCL-17, CCL-18Z CCL-22, CCL-24)
Growth factors
(TGF-piz PDGF, VEGF, EGF)
Arginine

Secrete
Pro-inflammatory cytokines
(e.g. TNF, IL-ip, IL-6)
Chemokines
(e.g. CCL5ZCXCL-1Z CXCL-10)
Free radicals
(iNOS)

Figure 2-6. Wound macrophages are broadly categorized into two phenotypes: the
pro-inflammatory M1 and the anti-inflammatory M2 phenotype.
[Adapted from (Hesketh et al. 2017a)]

2.2.3 Abnormal inflammation and cutaneous wound healing

As explained in earlier sections, a controlled inflammatory response is
critical for proper cutaneous wound healing. Figure 2-7 illustrates the effects of

abnormal inflammation on the quality of wound repair. The important take-away
from this diagram is that persistent inflammation can lead to non-healing wounds,
such as occurs in diabetic ulcers or pressure ulcers (Eming et al. 2009).
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Figure 2-7. Abnormal inflammation results in improper or insufficient wound healing.
[Adapted from (Eming et al. 2009)]

2.3

Hyaluronan: Introduction
As mentioned above, HA is an important molecule of the extracellular matrix

that regulates different phases of wound healing. HA is a high molecular weight,
non-sulfated glycosaminoglycan (GAG), composed of long chains of repeated

disaccharide sub-units of glucuronic acid (GlcA) and N-acetylglucosamine
(GlcNAc) as shown in Figure 2-8 (Hascall and Esko 2009). Unlike other GAGs, HA
is not synthesized in the Golgi apparatus, but is instead synthesized on the

cytosolic side of the plasma membrane of cells, and then extruded into the
extracellular space (Itano and Kimata 2002; Wang and Hascall 2004). Three

different membrane-bound enzymes are present in mammals and synthesize HA.

The hyaluronan synthase (HAS) genes are: HAS1, HAS2 and HAS3. In contrast,
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another group of enzymes called hyaluronidases (HYALs) degrade HA (Fraser and

Laurent 1989; Stern and Jedrzejas 2006; Tammi et al. 1988). The most widely

expressed members of the human hyaluronidase (HYAL) family are HYAL 1, 2, 3
and 4, and are highly tissue specific (Stern and Jedrzejas 2006).

N-acetylglucosamine

Glucuronic acid

Figure 2-8. The disaccharide unit of hyaluronic acid.
This unit is repeated to form a molecule of tremendous size, up to 2 x 106 Daltons.

Each of the three HAS enzymes produce different-sized HA chains, ranging
anywhere from 2 * 105 Da to more than 2 * 106 Da (Table 2-1) (Itano and Kimata

2002). Among these, HAS2 is known to produce the largest HA molecules. Also,

it has been found that if the gene for HAS2 synthase is removed, it causes

embryonic lethality in mice because of severe cardiac and vascular deformities
(Camenisch et al. 2000). Removing HAS1 and/or HAS3 synthase genes, however,

does not present any major phenotypic differences, indicating that HAS2 is the
most important hyaluronan synthase during embryonic development. The size of
HA is very significant in determining its effect. For example, high molecular weight
HA (HMW-HA) plays protective functions in maintaining vessel integrity and

endothelial permeability. HMW-HA can form a coiled structure on the endothelium,
thus limiting direct access of blood cells and plasma factors to the endothelial cells
(Lennon and Singleton 2011). Depending on its size, HA can also have pro- or

anti-inflammatory functions (Rayahin et al. 2015; Weigel et al. 1986).
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Table 2-1. Three different types of HASs produce different sized hyaluronic acid (HA)
in mammals.
While HAS2 produces larger molecular weight HA, HAS1 and HAS3 are known to produce
relatively smaller HA molecules.

Hyaluronan
synthase (HAS)

HAS1

HAS2
HAS3

Size of hyaluronic
acid (HA) produced

2 X 105 to 2 X 106 Da

> 2 X 106 Da
2 X 105 to 2 X 106 Da

Functions

Upregulation noted in inflammatory diseases such
as osteoarthritis and rheumatoid arthritis

Associated with tumor progression (Siiskonen et al.
2015)
Source of HA in cardiac
(Camenisch et al. 2000)

morphogenesis

Plays crucial role in gut inflammation (Kessler et al.
2015)

HA is an important ECM component that is ubiquitously distributed in

mammalian connective, epithelial, and neural tissue (Itano and Kimata 2002). A

gooey material, HA is highly hydrophilic and capable of holding a large amount of
water. Because of this, HA contributes to the viscoelastic properties of the vitreous

humor in the eye, and to the lubricating properties of synovial fluid of articular joints
(Sebag 1987; Swann et al. 1974). Similarly, HA helps to maintain the elasticity of

skin tissue, and its hydrating properties makes HA a very popular ingredient in
topical creams and cosmetics (Hascall and Esko 2009).

2.3.1 Hyaluronan in cutaneous wound healing
Originally, HA was considered to be just an inert extracellular matrix
component, essentially a “filler”. However, HA has now been found to participate

in the active regulation of many cellular behaviors (Maytin 2016; Noble 2002;

Tammi et al. 2002; Turley et al. 2002). HA in the ECM participates in intracellular
signaling by binding to cells via a plasma membrane receptors called CD44, and
to a soluble protein called Receptor for HA-mediated motility (RHAMM, CD168)
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(Turley et al. 2002; Underhill 1992). HA regulates cell proliferation and migration

during embryogenesis (Toole 2001), wound healing (Nagy et al. 2010; Stenson
2010), and tumor growth (Toole et al. 2002). Additionally, HA is known to affect

angiogenesis (Pardue et al. 2008), a process that involves activation of the HA
receptors CD44 and RHAMM (Slevin et al. 2007).

HA has been shown to regulate keratinocyte migration in the epidermis,

thus affecting cutaneous wound healing (Mack et al. 2003). Also, the role of HA in
inflammation during wound healing is a highly researched area (Back et al. 2005;
Mack et al. 2012; Nagy et al. 2010; Neudecker et al. 2004; Stenson 2010).

2.3.2 HA modification

Although structurally a very simple molecule, HA can be modified by binding
to various glycoproteins (9). Proteoglycans such as aggrecan and versican contain
an HA binding region (HBR) in their N-terminus which facilitates binding to HA

(Figure 2-9). Versican, aggrecan, and similar molecules are therefore called
hyaladherins (Iozzo and Murdoch 1996; Wight et al. 2013). Another more recently-

identified hyaladherin, one that actually modifies HA, is a protein called TNFa
stimulated gene-6 (TSG-6). The latter is discussed in more detail below.

Figure 2-9. Structure for Versican and Aggrecan showing the HA binding region (HBR)
(Adapted from (Iozzo and Murdoch 1996))
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2.4

Inter-a-trypsin inhibitor (IaI)

The IaI family of proteins are produced mostly in the liver, and are present
in the blood in high amounts (Zhuo and Kimata 2008). These proteins are
composed of a common light chain comprising a GAG chain, chondroitin sulfate
(CS), covalently attached to a core protein (bikunin protein, decorated with two
closely related heavy chains (HCs). There are 6 different known genes encoding

human HCs. HC 1 and 2 are the predominant isoforms in human IaI; HC3 along
with CS and bikunin form the pre-a-trypsin inhibitor (PaI). HC 4 and 5 are not as

well-defined as the first three isoforms. HC 4 exist as a free HC in circulating blood
and does not bind to bikunin. HC 5 is localized to only a few organs including

mammary glands, ovaries, uterus, thyroid, and is most common in the placenta
(Zhuo and Kimata 2008).
2.5

TSG-6 overview

2.5.1 Introduction, and TSG-6 regulation
TSG-6 protein is a member of the hyaluronan (HA) binding protein family,

first characterized by Lee et al. in 1992 in TNFa treated normal human fibroblast

cell lines (Lee et al. 1992). The TSG-6 gene codes for a glycoprotein of about 30
35 kDa, consisting of a Link domain at its N-terminus and a CUB domain

(Complement components Cls/Clr, uEGF, BMP1) at the C-terminus (Milner and
Day 2003). The Link domain contains a sequence similar to sequences in CD44,

aggrecan, and versican, all of which bind HA (Lee et al. 1992; Neame et al. 1987).
Figure 2-10 shows the modular structure of TSG-6, with the HA binding sequence
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of amino acids in the Link domain in purple, and the CUB domain in green. The
function of the CUB domain has not been determined yet.

Figure 2-10. Modular structure of TSG-6
[Adapted from (Milner and Day 2003)]

TSG-6, as the name suggests, is induced by the inflammatory cytokine

TNFa, as well as interleukin (IL-1). TSG-6 is being widely investigated for its role
in inflammation and inflammation-like conditions. While mostly absent in normal

tissues, TSG-6 is constitutively present in cumulus cell-oocyte complexes (COCs)
during their expansion (Fulop et al. 1997a). Along with its ability to bind to HA,
TSG-6 can interact with inter-alpha trypsin inhibitor (IaI, discussed later in this

section) and enhances its plasmin proteolysis inhibition activity. These features of
TSG-6 allow for its important role in the stabilization and expansion of the cumulus
matrix in the ovary. Expansion of COCs is an important phenomenon for egg cell

maturation; the absence of TSG-6 in TSG-6 null mice results in female infertility

(Day and de la Motte 2005; Fulop et al. 1997a).
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2.5.2 Functions of TSG-6
TSG-6 is known to play various functions in different inflammatory

conditions (Day and Milner 2018). Here, we discuss a few of these roles of TSG-6

in inflammation as described in the literature (Figure 2-11).

Figure 2-11. TSG-6 is a multifunctional protein.
Shown are some of the roles of TSG-6 that are interrelated and collectively affect inflammation.

2.5.2.1 TSG-6 in HA modification (HC-HA formation)

An important HA modification primarily attributed to the enzymatic activity

of TSG-6 is the transfer of heavy chains (HC) from Inter-a-trypsin inhibitor (IaI) to
HA (Day and de la Motte 2005). TSG-6 covalently binds to the HCs of IaI, and then
catalyzes the transfer of HCs to HA (Figure 2-12). The covalent binding of TSG-6

to HA, and of HC to HA, have been implicated in the cross-linking of HA and the

formation of HA cables. HC-HA complexes were thought to be present exclusively
in inflammatory tissues (Baranova et al. 2011; Colon et al. 2009; Lauer et al.

2015a). However, our preliminary data show that HC-HA (and TSG-6) are present
in normal, unperturbed skin. This is discussed in more detail later.
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Inflammation

TSG-6 covalently
binds to HC from lal,
and transfers the HC
to HA forming HC-HA
complex

TNFa, IL-1

HC-HA complex
(Large HA molecule
decorated with HCs)

Figure 2-12. Schematics for transfer of IaI HC to HA.
(Figure legend: Green blobs= HC; Blue rectangle= Bikunin; Black C-shaped curve= CS,
Orange triangle= TSG-6; Black consolidated structure= HA)

2.5.2.2 TSG-6 in neutrophil recruitment
TSG-6 is mostly known as an anti-inflammatory protein that is upregulated

in inflammatory conditions as a protective feedback mechanism. It has been shown

to inhibit neutrophil recruitment into the site of inflammation (Bardos et al. 2001;
Choi et al. 2011). In an air-pouch model of inflammation in murine skin, injection

of the Link module of TSG-6 caused attenuation of neutrophil migration into the
tissue (Getting et al. 2002). Moreover, application of recombinant TSG-6 (rTSG-6)

or mesenchymal stem cells (MSCs) in multiple models of skin wounds have shown
to result in reduced neutrophil recruitment to the wound area (Qi et al. 2014; Wang
et al. 2015). Similarly, in models of corneal wounding in mice and rabbits, treatment
with either injection of rTSG-6 or TSG-6 producing stem cells were demonstrated

to suppress neutrophil infiltration (Hertsenberg et al. 2017; Kim et al. 2014a; Oh et
al. 2010). Additionally, loss of TSG-6 in TSG-6 null mice has been correlated to

increased neutrophil migration in mouse peritonitis and arthritis models. This effect

29

of TSG-6 on neutrophil recruitment has been attributed to the ability of TSG-6 to
interact with HA, which modulates CD44-mediated attachment of leukocytes to the
endothelium (Szanto et al. 2004).

2.5.2.3 TSG-6 in chemokine binding
One of the mechanisms by which TSG-6 has been shown to inhibit

neutrophil migration as described by Dyer et al. is by its ability to bind to multiple

chemokines from the CXC and CC families with variable affinity, via its Link module
(Dyer et al. 2016; Dyer et al. 2014). CXCL8 (or IL-8) is a major pro-inflammatory
chemokine that regulates neutrophil migration. TSG-6 was preliminarily found to

bind to CXCL8 at a site close to the GAG binding site on CXCL8 (Dyer et al. 2014).
Thus, it was proposed that the interaction between TSG-6 and CXCL8 antagonizes

the binding of CXCL8 to GAGs such as heparan sulfate on the vascular
endothelium. Also, TSG-6/CXCL8 binding was thought to interfere with the

interaction of the chemokine to its ligand, thus resulting in inhibited neutrophil

migration. Further, Dyer et. al. (Dyer et al. 2016) showed that TSG-6 can bind to
other chemokines such as, CXCL4, CCL2, and CCL5, again limiting their

interaction with the GAGs. This causes a disturbance in chemotactic gradient
which is required to direct the migration of leukocytes ultimately resulting to

inhibited migration of the inflammatory cells.
2.5.2.4 TSG-6 in macrophage polarization

Macrophage, as explained in earlier sections, is an important type of
inflammatory leukocyte performing various functions in inflammation and wound
healing. TSG-6 has been shown to promote the polarization of inflammatory
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macrophages to anti-inflammatory or tissue reparative M2 phenotype. In a study

by Mittal et. al., mice lacking TSG-6 were found to be more prone to LPS induced
inflammatory lung injury with increased mortality, whereas, WT mice when treated
with rTSG-6 had reduced inflammation. This was accompanied by macrophage

population expressing higher level of M2 makers- CD206, Arginase-1 and Chi3l3
(Mittal et al. 2016). In a type 1 diabetic mouse model of corneal epithelial

inflammatory wound, treatment with MSCs upregulated TSG-6 expression,
reduced inflammation, and promoted healing, similar to rTSG-6 treatment. Flow

analysis of F4/80+ macrophages from rTSG-6 or MSC treated corneas presented

lower number of pro-inflammatory M1 phenotype macrophages and significantly
higher number of M2 phenotype macrophages (Di et al. 2017). In a mouse model

of

dextran

sulfate

sodium

induced

inflammatory

bowel

disease,

the

intraperitoneally administered MSCs released TSG-6, reduced inflammatory
response, and improved disease activity index, in conjunction with increased

CD206+ M2 macrophages. The M2 macrophage polarization was reportedly
abrogated when TSG-6 was silenced in MSCs using small interference RNA

(siRNA) (Song et al. 2017).
Moreover, TSG-6 from cells have been shown to modulate macrophage

phenotype in in-vitro cell cultures. Macrophages derived and differentiated from

monocytes, when co-cultured with activated dermal fibroblasts or MSCs, were
found to polarize more towards the M2 phenotype. This polarization was mediated

by TSG-6 released by activated dermal fibroblasts or MSCs as verified by
knockdown of TSG-6 with siRNA. (Ferrer et al. 2017; Song et al. 2017).
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2.6

TSG-6 and HC-HA complexes in diseases

TSG-6, as mentioned above, is stimulated by inflammatory cytokines TNFa,
as well as by IL-1, in vivo (Wisniewski et al. 1993). Under stimulation by these

cytokines, TSG-6 is produced by a variety of cell types including fibroblasts and
inflammatory cells, specifically neutrophils. TSG-6 has been widely discussed as
a protein having anti-inflammatory activity (Wisniewski et al. 1996; Wisniewski and
Vilcek 1997) although its role during inflammation remains controversial. Also, the

presence of TSG-6 and HC-HA complexes have been associated with different

inflammatory conditions such as, arthritis (Szanto et al. 2004; Wisniewski et al.
1994), colitis (Sala et al. 2015), gingivitis (Beltran et al. 2015), peritonitis, and

asthma related inflammation of airway epithelium (Lauer et al. 2013; Swaidani et
al. 2013). The generation of the TSG-6 null mouse by Szanto et al. (Szanto et al.

2004) has provided a valuable platform to study its role in these inflammatory

diseases.

Asthma/airway: Swaidani et al. (Swaidani et al. 2013) showed that TSG-6

null mice had decreased airway inflammation after induction of allergic airway

diseases. This was marked by a decrease in the amount of pulmonary HA. Also,
in comparison to wild-type (WT) littermates, TSG-6 null mice were resistant to
airway hyperresponsiveness and presented improved lung mechanics after
irritation induction. This suggests that TSG-6 aids in the pathogenesis of asthma.

Lauer et al. (Lauer et al. 2013) showed that the amount of HA synthesis by airway
smooth muscle cells is increased when recombinant human TSG-6 (rhTSG-6) is

used in cell culture, which is consistent with the decreased HA seen in the TSG-6
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null mouse. Moreover, the amount of HA was found to increase in a severe murine
asthma model, but HC-HA was only found to increase in non-severe asthma,

indicating the involvement of HC modification of HA in asthma severity (Lauer et
al. 2015a).

Arthritis/Cartilage: Arthritis is one of the most studied diseases in terms of
determining the role of TSG-6 in inflammation. Wisniewski et al. (Wisniewski et al.

1993) showed that TSG-6 is present in high levels in the synovial fluids of human
arthritic patients. It was determined that the patient’s synoviocytes constitutively
produce TSG-6 protein, and that TSG-6 is increased after TNFa or IL-1 treatment.

Another study by Bardos et al. (Bardos et al. 2001) in an autoimmune murine
model of arthritis showed that addition of recombinant mouse TSG-6 (rmTSG-6)

to acutely inflamed joints caused a reduction in edema, through immobilization of
CD44-bound HA.

Skin/scarring: TSG-6 was characterized for the first time in human normal

skin fibroblasts (Lee et al. 1992), where TSG-6 protein was found to be expressed
when cells in culture were treated with inflammatory ctyokines TNFa and IL-1.
Recently, a few studies have been done to determine the effects of TSG-6 in
scarring. Tan et al. (Tan et al. 2011) characterized the differential distribution of

HA and TSG-6 in different scar types from human skin- normal scars, keloid scars,

and adjacent unscarred skin. Immunohistochemistry performed on skin sections

showed that scars as well as unscarred tissues stained positive for TSG-6, as well
as for HC1, HC2, and bikunin, suggesting the presence of IaI. However, the study
is missing more quantitative data. Another study by Qi et al. (Qi et al. 2014) showed
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that intradermally implanted MSCs release TSG-6 in murine skin; compared to

control wounds, the MSC implanted wounds healed faster with less fibrosis. This
phenotype was demonstrated to be accompanied by decreased macrophage

activation, negative regulation of TNFa, and reduced granulation tissue formation.
Thus, TSG-6 could be anti-inflammatory in cutaneous wounds. Moreover, Wang

et al. (Wang et al. 2015) investigated the effect of rhTSG-6 on rabbit ear wound
models. Compared to sham injections, it was shown that wounds receiving rTSG-

6 healed with less hypertrophic scar.
2.7

Summary

Understanding the normal underlying biology and microenvironment of the
wound is crucial to understanding the possible abnormalities in wound healing.

Such understanding will eventually aid in the development of new therapeutics and
treatment modalities. As discussed above, the few studies available in cutaneous

wound models suggest that TSG-6 plays an important role in cutaneous wound

healing. The TSG-6 null mouse provides an ideal vehicle to define the mechanistic

roles of TSG-6 in wound repair. Also, results from studies with the TSG-6 deficient
model might provide further rationale for the possibility of using TSG-6 as a
therapeutic tool to enhance wound healing.
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CHAPTER III
CUTANEOUS WOUNDS IN MICE LACKING TUMOR NECROSIS FACTOR-

STIMULATED GENE-6 EXHIBIT DELAYED CLOSURE AND AN ABNORMAL

INFLAMMATORY RESPONSE
3.1

Introduction
Cutaneous wound healing is a complex process that involves inflammation,

keratinocyte/fibroblast proliferation, migration, angiogenesis, extracellular matrix

(ECM) deposition and remodeling, all orchestrated by the specific actions of

cytokines, chemokines, growth factors, and enzymes (Barrientos et al. 2008; Clark
2001; Martin 1997; Singer and Clark 1999). One of these enzymes is Tumor

necrosis factor (TNF)-stimulated gene-6 (TSG-6) protein, also known as
TNF-induced protein 6 (Tnfip6 or Tnfaip6). TSG-6, first identified by Lee et al. (Lee

et al. 1990) in human foreskin fibroblasts stimulated with the pro-inflammatory
cytokine TNFa, encodes a secretory glycoprotein with a molecular weight of ~3035 kDa (Milner and Day 2003; Mittal et al. 2016; Wisniewski et al. 1993).

Functionally, TSG-6 appears to play important roles in ECM modification
and in tissue inflammation. One of its important enzymatic activities is to catalyze
the covalent transfer of heavy-chain (HC) protein from inter-alpha-trypsin inhibitor
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(IaI) and pre-a-inhibitor (PaI) to hyaluronan (HA) forming HC-HA complexes

(Colon et al. 2009; Jessen and 0dum 2003; Mukhopadhyay et al. 2004). Due to
this activity, TSG-6 has an important role in the stabilization and expansion of
cumulus cell-oocyte complexes (COCs), a phenomenon vital for egg cell

maturation, and thus accounting for female sterility in the TSG-6 knock-out (KO)

mouse (Fulop 2003; Fulop et al. 1997b; Salustri et al. 1999; Salustri and Fülop
1998). Additionally, TSG-6 protein is able to inhibit neutrophil migration via the
TSG-6 Link domain (Cao et al. 2004; Getting et al. 2002) which intracts with

neutrophil chemokines such as human CXCL8, and with glycosaminoglycans on
endothelial cell surfaces (Dyer et al. 2016; Dyer et al. 2014). Furthermore, TSG-6,

as well as HC-HA complexes, have been shown to promote the polarization of
macrophages to an alternatively activated/ anti-inflammatory M2 phenotype

instead of the classically activated/ proinflammatory M1 phenotype (Ferrer et al.
2017; He et al. 2013; Mittal et al. 2016). Given the ability of TSG-6 to regulate the

behavior of neutrophils and macrophages, we postulated that TSG-6 may be
important in cutaneous wound healing. However, evidence for this prior to our
study was largely indirect.

TSG-6, although is generally absent in normal tissues, has been reported
to be constitutively present in human amniotic membrane epithelial and stromal
cells (Zhang et al. 2012), in the normal murine pancreatic islets (Hull et al. 2012),

and in astrocytes in rodent adult central nervous system (Coulson-Thomas et al.
2016). One hint to its possible importance in inflammation is the fact that TSG-6

expression can be greatly stimulated by pro-inflammatory cytokines and growth
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factors including TNFa, interleukin-1 (IL-1), and lipopolysaccharide (LPS), in
fibroblasts, inflammatory cells, and endothelial cells among other cell types (Milner

and Day 2003). Another fact that suggests a central role for TSG-6 is the manner

in which it is regulated in inflammatory diseases such as arthritis. In a study by
Wisniewski et al., the synovial fluids from rheumatoid and osteoarthritis patients

were shown to have a high level of TSG-6 which was otherwise absent in nonarthritic joints. It was determined that the patient’s synoviocytes constitutively
produce TSG-6 protein, that it is increased after TNF or IL-1 treatment, and its
activity exerts anti-inflammatory effects (Wisniewski et al. 1993). In murine models

of experimental arthritis, the addition of recombinant TSG-6 (rTSG-6) to acutely
inflamed joints lessened edema by immobilization of CD44-bound HA (Bardos et
al. 2001) and had a chondroprotective effect. Another study with a cartilage

specific TSG-6 transgenic mouse showed less damage on articular cartilage upon
induction of arthritis (Glant et al. 2002). Conversely, the absence of TSG-6 in a
TSG-6 null arthritic mouse model led to more severe destruction of the articular

cartilage and bone accompanied by increased neutrophil infiltration into the

synovium (Szanto et al. 2004).

In a number of recent studies, the introduction of exogenous TSG-6 protein
into various models of inflammation has mostly shown a protective effect. For
example, in models of corneal injury in rabbits (Oh et al. 2010) or rats (Kim et al.

2014a), injection of rTSG-6 into the anterior chamber of eye exhibited reduced
mRNA expression of pro-inflammatory cytokines, such as TNFa and IL-1,

decreased level of myeloperoxidase, and reduced neutrophil infiltration in compare
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to PBS only controls. In a mouse model of inflammation-related dry eye syndrome,
application of rTSG-6 increased tear production while decreasing expression of

pro-inflammatory cytokines (Lee et al. 2015). In a gingival wound model in rats, a

relative reduction in levels of MPO, IL-1b, IL-6, and neutrophils infiltration were
observed after an injection of rTSG-6 into the wounds (Beltran et al. 2015).
Activated mesenchymal stem cells (MSCs) are a good source of exogenous TSG-

6, and have been explored for inflammation management (Lee et al. 2016; Prockop
and Youn Oh 2012). In mouse models of myocardial infarction (Lee et al. 2009),
peritonitis (Choi et al. 2011), or dextran sulfate sodium (DSS) induced colitis,
injection of MSCs or rTSG-6 led to increased levels of serum TSG-6, decreased

inflammation, decreased disease activity, and/or improved recovery, while

knockdown of TSG-6 in MSCs negated these effects (Sala et al. 2015). In the DSSinduced colitis mouse, injection of MSCs appeared to improve colitis by lowering

proinflammatory markers and increasing the proportion of anti-inflammatory

(tissue protective) M2 macrophages (Song et al. 2017). In contrast with most
inflammatory disease models in which TSG-6 appears to correlate with reduced
inflammation, murine models of asthma are a notable exception, wherein the
opposite appears to be true (Lauer et al. 2015b; Lauer et al. 2013; Swaidani et al.

2013).

In skin biology, very few studies on TSG-6 have been performed to date.
One study used immunohistochemistry to demonstrate the presence of TSG-6,
and heavy chains HC1 and HC2, in human scars and keloids, but was qualitative

in nature (Tan et al. 2011). Another study showed that intradermally implanted
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MSCs released TSG-6 in murine skin, and that relative to control wounds, the
MSC-implanted wounds healed faster and had less fibrosis, less macrophage

activation, lower TNFa levels, and reduced granulation tissue formation (Qi et al.
2014). A third study investigating the effect of rTSG-6 on rabbit ear wounds

showed that, wounds injected with rTSG-6 healed with less hypertrophic scar than
wounds receiving sham injections (Wang et al. 2015).
Thus, the few available studies suggest that TSG-6 may play an anti

inflammatory role in cutaneous wound healing. The aim of our study is to test this
hypothesis by examining what consequences the elimination of endogenous TSG-

6 might have upon the normal course of wound repair in a knockout (TSG-6 null),
and to thereby gain more information about TSG-6 as possible therapeutic tool to
enhance wound healing.

3.2

Materials and Methods

3.2.1 Animals

C57BL/6J wild-type (WT) mice were obtained from JAX Laboratories

(Bar Harbor, ME). TSG-6 null mice, whose generation was described by Fulop
et al. (Fulop 2003), in C57BL/6 background was generously provided by Dr.

Mark Aronica in our institute. All mice were maintained per guidelines of the
American Association for the Accreditation of Laboratory Animal Care. All

procedures were approved by the Cleveland Clinic Institutional Animal Care

and Use Committee.
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3.2.2 Wounding experiments
Mice (WT, or TSG-6 KO, male and female, 8-10 weeks of age) were
anesthetized with an intraperitoneal injection of Ketamine-Xylazine and fur

shaved from the upper back with an electric razor. After letting the skin recover

overnight, two full-thickness excisional wounds were made using 5 mm punch
biopsies (Acuderm, Fort Lauderdale, FL), under anesthesia. To follow wound
closure, mice were anesthetized with isofluorane and photographed from a

fixed distance using a digital camera on a stand at Days 0, 3, 5, 7 and 10 post
wounding. The wound area (in pixels) was determined from the digital photos
using IPLab Spectrum imaging software (Scanalytics, Rockville, MD). For

histological examination, wounds were harvested at 12 hours, Days 1, 3, 5, 7
and 10 post wounding, along with unwounded skin. Tissues were fixed in
Histochoice (Amresco, Solon, OH), paraffin embedded, and stored for later

sectioning. Wounds were also harvested at different time points along with
unwounded tissues, flash frozen in liquid nitrogen, and stored at - 80 °C for

subsequent protein and RNA isolation.

3.2.3 Histological assessment of wound closure
Histochoice-fixed, paraffin embedded wound tissues from 12 hours to
Day 10 post wounding were cut into 5-micron sections using microtome. After

rehydration, the sections were stained for Hematoxylin and Eosin (H&E) using
standard procedure. The mounted slides were then scanned using an Aperio
AT2 slide-scanner (Leica Biosystems, Buffalo Grove, IL). The scanned images

were analyzed for histological wound closure using Aperio ImageScope (Leica
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Biosystems).

Percentage

re-epithelialization

(or

epidermal

gap)

was

determined by measuring the length of epidermal tongue at both wound edges

and the total wound length from wound edge-to-edge.
3.2.4 Western Blotting

Unwounded and excisional wound skin samples stored at - 80 °C were
processed for protein isolation as follows - tissues were first pulverized in a
chilled

Bessman tissue pulverizer, resuspended

in cell lysate buffer

(Raybiotech, Inc., Peachtree Corners, GA) with 1X protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO), and then homogenized and sonicated. Protein

in the supernatant was collected after centrifugation and quantified using
Bradford assay. Chemiluminescent Western blotting was performed as per

standard procedure. Protein lysates were electrophoresed in NuPage 4-12 %
Bis-Tris gels (Invitrogen, Carlsbad, CA) and blotted onto PVDF membranes.

The blots were probed overnight at 4 °C with one for the following primary
antibodies: Anti-TSG-6 mouse monoclonal (1 ^g/ml; Millipore, Burlington, MA);

rat monoclonal TNFa (1 ^g/ml; BioXCell, West Lebanon, NH); rabbit
monoclonal Arg1 (1:1000, Cell Signaling Technology, Danvers, MA); rabbit

anti-mouse Actin (1:1000; Santa Cruz Biotechnology, Dallas, TX). This was
followed by 1.5-hour incubation at room temperature with an anti-rat or anti

rabbit horseradish

peroxidase

(HRP)-conjugated

secondary antibodies

(1:10,000; Jackson ImmunoResearch, West Grove, PA). Chemiluminescent

detection was performed using Amersham™ ECL™, or ECL™ prime reagent

kit (GE Healthcare, Chicago, IL). The protein bands were quantified using
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IPLab Spectrum imaging software (Scanalytics) with actin as the loading
control.

3.2.5 Evaluation of HC modification of hyaluronan (HC-HA analysis)

HC-HA analyses was performed as described by Lauer et al. (Lauer et
al. 2015a). Briefly, unwounded and excisional wound skin tissues were
collected, weighed and minced in PBS at 1 pl volume per 0.33 mg of tissue.

Streptomyces hyaluronidase (Millipore) was added at 20 TRU/ml for extraction
of HCs, or equal volumes of PBS for No-hyaluronidase controls, incubated at

30 minutes on wet-ice followed by 30 minutes at 37 °C. After centrifugation at

13,000 x g, supernatants were collected into clean labeled tubes. Equal
amounts of samples were electrophoresed in NuPage 4-12 % Bis-Tris gels and

blotted onto PVDF membranes. Blots were then incubated with anti-IaI rabbit

polyclonal Dako antibody (1:8000; Agilent Technologies, Santa Clara, CA),
followed by IRDye® 800CW donkey anti-rabbit secondary antibody (1:15,000;

LI-COR Biosciences, Licoln, NE). Blots were imaged on an Odyssey infrared
imaging system and the bands for HC (at around 85 kDa) were quantified using
ImageStudio™ (LI-COR Biosciences).

3.2.6 Immunostaining for neutrophils and macrophages
Histochoice-fixed, paraffin embedded wound tissues were cut into 5-

micron sections using microtome. After rehydration, the sections were blocked
with 3% normal goat serum for 30 minutes at room temperature. Sections were

then incubated overnight at 4 °C with the respective primary antibodies in
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blocking buffer: Anti-Ly6G rat monoclonal (1:100; Affymetrix, Santa Clara, CA)

for neutrophils; anti-F4/80 rat monoclonal (1:100; Bio-Rad, Hercules, CA) for
macrophages. A biotinylated goat anti-rat biotin secondary (1:300) was
followed by Vectastain ABC reagent (Vector Laboratories, Burlingame, CA) for

30 minutes each. DAB peroxidase substrate kit was used for detection followed

by VectaMount mounting medium for mounting.

For analysis, slides were scanned using an Aperio AT2 slide-scanner
(Leica Biosystems). IPLab Spectrum imaging software (Scanalytics) was used

to determine the positive staining for neutrophils or macrophages in the wound
bed. A common threshold was set to encompass the pixels with dark brown

DAB positive stains, and areas per unit wound length was determined using
the Breadloaf method. Regions of interest (ROIs) 500 pixels wide were chosen

across the wound length and four consecutive ROIs were averaged to get a
data point. A minimum of 15 data points, derived from at least 4 wounds, were

analyzed per condition.

3.2.7 Immunostaining for macrophage phenotypes
Serial wound sections were incubated overnight at 4 °C with the
respective primary antibodies: rabbit anti-mouse CD38 (1:100; Bioss, Woburn,
MA) for M1 macrophages; rat monoclonal F4/80 (1:100; Bio-Rad) for all

macrophages; rabbit monoclonal Arg1 (1:100; Cell Signaling Technology) for
M2 macrophages. Antigen retrieval using citrate buffer at pH 6.0 was performed

for anti- CD38 and anti- Arg1 antibodies. Sections were then incubated with
goat anti-rat or goat anti-rabbit biotinylated secondary antibody (1:300; 30 min;

43

Vector Laboratories) followed by incubation with Alexa Fluor 488 Streptavidin

(1:500; 1.5 hour, Invitrogen), and mounted in VECTASHEILD mounting

medium (Vector). Using a Leica DM upright microscope (Leica Biosystems),
corresponding images were captured for each antibody type by tracing a

common landmark. For each image captured, cells stained positively for
macrophage phenotype marker (M1 or M2 marker) and the pan-macrophage

F4/80 marker were counted, and the ratios determined.
3.2.8 Recombinant TSG-6 injection
Mice were shaved and anesthetized as described above and two full

thickness excisional wounds were made using 5 mm punch biopsies.
Recombinant human TSG-6 (rTSG6, R&D systems, Minneapolis, MN) was

prepared at 2 pg in 100 pl PBS. The edge and center of wounds were injected

with rTSG6 (+ rTSG6) or equal volume of PBS (Vehicle control, VC) right after
wounding on Day 0 and on Day 4 post wounding. Wounds were photographed

as above to evaluate wound closure. Wounds were also made and collected at

12 hours and Day 7 post wounding to evaluate for neutrophils and
macrophages infiltration as above.

3.2.9 Flow cytometric analysis for M1 and M2 macrophages
Single cell suspensions from Day 5 wounds were prepared as described
(Bannon et al. 2013) with modifications as explained in Chapter IV. Briefly,

wounds were isolated from WT and TSG-6 null animals and weighed. Tissues
were rinsed once each in 70 % ethanol and PBS, cut into 2 mm2 pieces and

incubated overnight (4 °C) in 20 pl HBSS per mg of wound tissue with 1 mg/mL
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Dispase II (Sigma-Aldrich, St. Louis, MO), 3% FBS and 10 mg/mL G418
(Sigma-Aldrich). Tissues were transferred to 80 ul HBSS per mg wound tissue

with 1 mg/mL Collagenase I (Worthington, Lakewood, NJ), 75 U/mL DNaseI

(Worthington) and 5 mg/mL G418 and incubated for 2 hours (37 °C) with
shaking. Cell suspensions were filtered through a 40 pm cell strainer (Corning

Technology, Corning, NY) and washed twice with PBS buffer (PBS, 3% FBS,

0.1 mM EDTA), and centrifuged at 400 rpm. Cells were counted, resuspended
at 1 million cells/ml in PBS buffer, and labeled with fluorescently tagged

antibodies: Rat anti-mouse CD45 (1:200); rat anti-mouse F4/80 (1:80); rat anti

mouse TNFa (1:40; BioLegend, San Diego, CA); sheep anti-mouse Arg1 (1:10;
Novus Biologicals, Centennial, CO) for 25 minutes (4 °C). Samples were

analyzed on a BD LSRFortessa flow analyzer (BD Biosciences, Mississauga,
ON, Canada).

3.2.10 Statistical analysis

Numerical data were expressed as Mean ± SEM. All statistical analyses
were performed using SigmaPlot 12 (Systat Software Inc., San Jose, CA).
Normality of the data were tested using Shapiro-Wilk Normality test. Analyses

for two group comparisons were performed using either the two-tailed Student’s

t-test or Mann-Whitney Rank Sum test. For multiple group comparisons, either

One Way ANOVA or Two Way ANOVA with Bonferroni corrections were
performed. P-value £ 0.05 was considered statistically significant. (See
Appendix for full analysis.)
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3.3

Results

3.3.1 TSG-6 protein is present in unwounded murine skin and increases

post wounding

To determine the endogenous expression of TSG-6 in normal and injured

skin, Western analysis was performed on proteins from unwounded skin and full
thickness excisional wounds of wildtype (WT) mice (Figure 3-1a and b). TSG-6 is
constitutively expressed at low levels in unwounded skin and increases by more
than 4-fold as early as 12 h post-wounding. Expression peaks by 3 days, after

which it drops, but remains above baseline until at least day 10 (Figure 3-1b). This
shows that TSG-6 is upregulated after wounding, and suggests a possible

functional role in wound repair.
As mentioned above, TSG-6 catalyzes the covalent and non-covalent

transfer of heavy chains (HCs) from IaI and pre-aI to HA, forming HC-HA
complexes. HC-HA is thought to stabilize HA rich extracellular matrices, making it
more adhesive to inflammatory cells (Lauer et al. 2014; Rugg et al. 2005; Zhuo et
al. 2006; Zhuo et al. 2001). To quantify the levels of HC-HA in unwounded and

wounded WT skin, the assay shown in Figure 3-1c was performed. In the absence

of hyaluronidase, HC-HA complexes in the samples cannot enter the SDS-PAGE
gel, and remain trapped in the well due to their large size (Figure 3-1c, lane 3,
dashed box). However, after hyaluronidase treatment, HC-HA complexes are

degraded and HC is released, appearing as a band at ~85 kDa. The presence of
an HC band in the hyaluronidase-digested sample in lane 2 of Figure 3-1c shows
that HC-HA is constitutively present in normal unwounded skin. At 3 days post
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wounding, the HC band intensity increases by ~3 fold (Figure 3-1c, lane 4; Figure

3-1d). These changes mirror changes in expression of TSG-6 protein pre- and
post-wounding (Figure 3-1a and b).

Figure 3-1. TSG-6 protein and HC-HA are present in unwounded murine skin and
increase post wounding.
(a) Harvested wound sections were processed for protein extraction and analyzed using
Western blot analysis with Actin as the loading control. (b) TSG-6 is present in unperturbed
skin, significantly increases within 12 hours post wounding, peaks at Day 3 and is still
increased at Day 10 post wounding relative to unwounded skin. (c) The presence of a HC
band in the unwounded tissue extract treated with Streptomyces hyaluronidase (Hy’ase)
indicate that HC-HA is present de novo in unperturbed skin (Lane 2) HC-HA levels are
increased in a Day 3 wound (Lane 4) relative to uW skin. (d) When quantified using
ImageStudio, HC-HA from Day 3 ExW wounds significantly increased by more than 3 folds.
Statistical analysis was performed using One Way Repeated Measures ANOVA or Student’s
t-test. (n), number of animals.

3.3.2 There are no redundant enzymes that transfer HC to HA in the skin

To determine whether TSG-6 protein is the sole molecule responsible for

HC-HA complex formation in skin, we assayed HC-HA in extracts from the skin of
TSG-6 null mice biopsied pre- and post-wounding. TSG-6 protein expression was

absent in TSG-6 null mice as expected (Figure 3-2a). In unwounded skin, the HC
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band (85 kDa) normally seen in unwounded WT samples (Figure 3-2b, lane 2) was
absent in samples from unwounded TSG-6 null skin (Figure 3-2b, lane 4). At Day
1 post-wounding, a time when HC-HA complexes are strongly induced in WT

wounds (Figure 3-2b, lane 6), no HC band was detectable in TSG-6 null wounds
(Figure 3-2b, lane 8). These data verify that the loss of TSG-6 is responsible for
the inability to form HC-HA complexes, and no other molecule is induced that can
compensate and transfer HC from IaI to HA. Thus, this model was appropriate for

our study to understand the effect of loss of TSG-6 and HC-HA complexes on
cutaneous wound healing.

Figure 3-2. TSG-6 HC transfer activity is non-redundant in skin
(a) Western blot analysis of proteins from WT and TSG-6 null skin using anti TSG-6 antibody.
GAPDH was used as the loading control. (b) HC-HA assay was performed on unwounded and
Day 1 excisional wounded skin from TSG-6 null and WT controls. WT skin showed the
presence of HC band in the hyaluronidase treated sample (Lane 2, boxed band), which
increased after wounding (Lane 6) as expected. TSG-6 null samples were missing the HC
band both before and after wounding (Lane 4 and 8, dashed boxes).

3.3.3 The absence of TSG-6 results in delayed wound closure

Wound closure rate is an important indicator of proper wound healing. To
observe the effects of loss of TSG-6 upon cutaneous wound closure, excisional
wound areas were monitored over time in WT and TSG-6 null mice (Figure 3-3a
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and b). At all the time points post-wounding, the relative wound area was larger for
TSG-6 null wounds compared to WT wounds, demonstrating that loss of TSG-6

delays wound closure. Differences were statistically significant at Days 5, 7 and 10
post-wounding.
Day 0

Day 3

Day 5

Day 7

Day 10

b

Time post-wounding (days)

Figure 3-3. Loss of TSG-6 results in delayed wound closure
(a) Full-thickness excisional wounds in WT and TSG-6 null mice. White dotted lines denote
the open wound area; Bar= 5mm (b) Wounds were photographed and measured using IPLab
imaging software to determine the open wound area. Wound sizes are represented as the
percentage of that on Day 0. The wound areas were larger for the TSG-6 null wounds
compared to WT wounds for each time point post wounding. The difference was significant for
Days 5 and 7 and 10. Statistical analysis was performed using either Student’s t-test or MannWhitney Rank Sum test. Dashed line with closed circles= TSG-6 null, Solid line with open
circles=WT; N= 20 wounds, except for Day 10, N= 10 wounds.

3.3.4 Delayed wound closure verification: TSG-6 null wounds displayed
slower re-epithelialization

Histological analysis of WT and TSG-6 null wound sections was performed
to verify the delayed wound closure phenotype seen above. The H&E stained

slides were scanned, and epithelial tongue length was measured to determine the
percentage re-epithelialization over the original wound length (Figure 3-4i). While

negligible re-epithelialization was observed in 1-day wounds (image not shown),

re-epithelialization was clearly observed starting at 3-day post wounding (Figure
3-4a and b). Difference in re-epithelialization were significant in 5-day (Figure 3-4c

49

and d) and 7-day post wounding (Figure 3-4e and f). By 10 days (Figure 3-4g and

h), the wounds were almost completely epithelialized in both WT and TSG-6 null.
Thus, TSG-6 null wounds have delayed wound closure as verified by delayed re-

epithelization.
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Original wound length

A

Wildtype,
3 day wound

।

Migrating epithelial tongue
(yellow)

Original wound length

B

TSG-6 null,
3 day wound

Original wound length
■ Migrating epithelial tongue
। (yellow)

Wildtype,
5 day wound

*
Original wound length
TSG-6 null,
5 day wound

Figure 3-4. Delayed wound closure phenotype in TSG-6 null wounds were confirmed by
histological analysis of re-epithelialization.
H&E staining of WT and TSG-6 null wounds. Representative images for (a, b) 3-day wounds,
(c-d) 5-day wounds. Black lines above the full scans denote wound edges. Original wound
lengths were measured by tracing the distance between these two lines. The insets show
epithelial tongues on either side of the wound (black boxes in full scans). The yellow lines (in
full scans) and yellow dots (in insets) denote where the epithelial tongues were measured.
Scalebar (in the first inset)= 100 ^m
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Figure 3-4. (Continued) H&E staining of WT and TSG-6 null wounds. Representative images
for (e, f) 7-day wounds, (g-h) 10-day wounds. The black lines above the full scans denote
wound edges. Original wound lengths were measured by tracing the distance between these
two lines. Single inset per wound means the wounds were full re-epithelialized. Yellow lines
(in full scans) and yellow dots (in insets) denote where the epithelial tongues were measured.
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Figure 3-4. (Continued) (i) Percentage epithelialization is significantly lower in TSG-6 null
wounds at Day 5 and 7 post wounding, indicating delayed wound closure compared to WT
wounds. Statistical analysis was performed using either Student’s t-test or Mann-Whitney
Rank Sum test. (n), number of wounds.

3.3.5 The absence of TSG-6 results in differential regulation of neutrophil
infiltration into wound bed
Another critical measure of proper wound healing is the orchestrated

recruitment and clearance of inflammatory cells. Neutrophils are among the first to

arrive at the site of injury (Figure 3-5a to m). Interestingly, sections from early

wounds (at 12 h and 24 h) immunostained with the neutrophilic granule marker
Ly6G showed significantly fewer neutrophils in the TSG-6 null mice compared to

WT mice (Figure 3-5a to d). However, at later time points there were more
neutrophils in TSG-6 null wounds, particularly at Day 7 where the difference was

highly significant (Figure 3-5i and j). Thus, a differential pattern of neutrophil

recruitment and/or clearance was observed in the presence versus absence of
TSG-6 (and HC-HA) in cutaneous wounds (Figure 3-5m).
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Wildtype, 12 h wound

TSG-6 null, 12 h wound

Wildtype, 24 h wound

TSG-6 null, 24 h wound

Figure 3-5. Loss of TSG-6 results in an abnormal inflammatory response.
Neutrophil staining of WT and TSG-6 null wounds. Representative images for (a, b) 12 h
wounds, (c-d) 24 h wounds. The black lines above the full scans denote wound edges. The
black boxes in the full scans show where the position of the zoomed view provided in the
insets. The insets on the left show respective wound edges, while the insets on the right show
the middle of the wound bed. Scale bar (in the first inset) = 100 ^m
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Wildtype, 3 d wound

TSG-6 null, 3 d wound

Wildtype, 5 d wound

TSG-6 null, 5 d wound

Figure 3-5. (Continued) Neutrophil staining of WT and TSG-6 null wounds.
Representative images for (e, f) 3-day wounds, (g-h) 5-day wounds. The black lines above
the full scans denote wound edges. The black boxes in the full scans show where the position
of the zoomed view provided in the insets. The insets on the left show respective wound
edges, while the insets on the right show the middle of the wound bed.
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Figure 3-5. (Continued) Neutrophil staining of WT and TSG-6 null wounds.
Representative images for (i, j) 7-day wounds, and (k-l) 10-day wounds. The black lines above
the full scans denote wound edges. The black boxes in the full scans show where the position
of the zoomed view provided in the insets. The insets on the left show respective wound
edges, while the insets on the right show the middle of the wound bed.
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p < 0.005

12 h

24 h

Day 3

Day 5

Day 7

Wildtype

Day 10

Time post wounding
Figure 3-5. (Continued) (m) Neutrophil density was determined using IPLab. Neutrophil
recruitment is delayed in early wounds (12 hours and 24 hours), while an exacerbated
recruitment is seen at Day 7. Statistical analysis was performed using either Student’s t-test
or Mann-Whitney Rank Sum test. (n), number of animals.

3.3.6 TSG-6 null mice develop an abnormally pro-inflammatory wound
milieu
TSG-6 is known to have anti-inflammatory effects in other systems (Day

and Milner 2018). To assess the overall inflammatory status of wounds in TSG-6

null versus WT mice, we evaluated levels of TNFa protein in whole wound tissue
at different time points after injury, using Western analysis (Figure 3-6a).

Consistently higher levels of TNFa expression were found in TSG-6 null wounds
than in WT wounds at all time points including unwounded skin at baseline (Figure

3-6b). Thus, TSG-6 null wounds constitute a more pro-inflammatory environment
than WT wounds.
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Figure 3-6. Absence of TSG-6 results to a more pro-inflammatory wound milieu.
(a) Harvested WT and TSG-6 null unwounded and wound skin samples were analyzed using
Western blot analysis with Actin as the loading control. (b) TNFa expression is relatively higher
in TSG-6 null wounds at all time points including in unwounded skin. The difference is
significant at 12 hours and 7 days post-wounding. Statistical analysis was performed using
either Student’s t-test or Mann-Whitney Rank Sum test. (n), number of animals.

3.3.7 No difference in absolute macrophage number in TSG-6 null wounds
compared to WT wounds

To evaluate macrophages, we stained wound sections using the pan
macrophage marker F4/80. No significant differences in the relative number of
macrophages were observed between WT and TSG-6 null wounds, suggesting

that the absence of TSG-6 and HC-HA had no significant effect upon total

macrophage recruitment (Figure 3-7a and b).

Figure 3-7. No difference in macrophage recruitment observed in TSG-6 null wounds
compared to WT.
(a) Macrophage staining of WT and TSG-6 null wounds. (b) Macrophage density was not
significantly different in TSG-6 null wounds compared to WT for Days 5 and 7 post wounding.
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Statistical analysis was performed using either Student’s t-test or Mann-Whitney Rank Sum
test (n), number of animals. Bar = 100 um

3.3.8 TSG-6 null mice wound macrophages are polarized towards the pro-

inflammatory M1 phenotype at Day 7 post wounding.
TSG-6 has been shown to play an important role in polarization of
macrophages from a pro-inflammatory M1 to anti-inflammatory M2 phenotype. To
determine whether macrophages in TSG-6 null wounds might be relatively more

polarized toward an M1 phenotype compared to WT macrophages, we stained
Day 7 wound sections for CD38 (an M1 marker), along with F4/80, in adjacent

serial sections. Evaluation of these immunostains revealed that TSG-6 null wounds

contain significantly more CD38-expressing macrophages than in WT wounds
(Figure 3-8a). Next, we assessed the level of Arginase-1 (Arg1, an M2 marker) in
whole wounds (Figure 3-8c), both by immunostaining (Figure 3-8b) and by western
analysis (Figure 3-8e). We found that Arg1 is lower in TSG-6 null wounds at all

time

points

evaluated,

again

suggesting

a

more

pro-inflammatory

M1

macrophages in TSG-6 null wounds. To focus more closely upon the expression

of M1/M2 phenotypic markers in the macrophages themselves, single cells were
isolated from Day 5 wounds by dispase/collagenase digestion, followed by flow

cytometric analysis of macrophages. We found that in TSG-6 null mice, a higher
proportion of F4/80 positive macrophages expressed TNFa (a well-established M1
marker), while the proportion of macrophages expressing Arg1 was lower, relative

to WT wounds (Figure 3-8d and e). Thus, the absence of TSG-6 in null wounds

results in polarization of the overall macrophage population to a more
proinflammatory phenotype.
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TNFa specific fluorescence

TNFa specific fluorescence

Figure 3-8. Loss of TSG-6 polarizes cutaneous macrophages to more pro-inflammatory
and less anti-inflammatory phenotype.
Day 7 wounds were fixed, and paraffin embedded for immunostaining. (a) Parallel sections
from WT and TSG-6 null wounds were stained for an M1 macrophage (CD38) marker and a
pan macrophage marker (F4/80). The ratio of CD38 to F4/80 positive cells was significantly
higher in TSG-6 null wounds, indicating prevalence of more pro-inflammatory macrophages.
(b) Parallel sections from WT and TSG-6 null wounds were stained for an M2 (Arg1)
macrophage marker and a pan macrophage marker (F4/80). The ratio of Arg1 to F4/80 positive
cells was significantly lower in TSG-6 null wounds, suggesting less abundant anti-inflammatory
macrophages in null wounds. (c) Western blot analysis of Arg1 protein reaffirms our finding in
immunostaining. For each time point observed, the Arg1 protein expression is lower in TSG-6
null wounds compared to WT wounds. A preliminary flow cytometric analysis of single cell
suspension from Day 5 (d) WT and (e) TSG-6 null wounds also showed that CD45+F4/80+
double positive macrophages are more frequently TNFa positive /M1 type and less frequently
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Arg1 positive/M2 type in TSG-6 null wounds. Statistical analysis was performed using either
Student’s t-test or Mann-Whitney Rank Sum test. (n), number of wounds.

3.3.9 Reintroduction of recombinant TSG-6 into TSG-6 knockout wounds
restores normal healing

To confirm that the difference in wound closure observed in WT versus
TSG-6 null wounds was due to the loss of TSG-6, a protein rescue experiment was

performed. Recombinant TSG-6 protein (rTSG-6) was reintroduced at two time

points, i.e., immediately after wounding (Day 0) and at 4 days post-wounding
(Figure 3-9a). In TSG-6 null mice, wound sizes trended slightly lower at Days 1-5
in wounds receiving the rTSG-6 injections, and became significantly smaller (and
equal to control WT wounds) at Day 7 (Figure 3-9b and c). Interestingly, injection

of rTSG-6 into WT wounds worsened wound closure compared to the WT vehicle
control. These findings suggested that the delay in wound closure in TSG-6 null

wounds is attributable to loss of TSG-6.
To confirm that differences in neutrophil recruitment between WT and TSG6 null wounds were also due to loss of TSG-6, a similar TSG-6 reintroduction

experiment was performed. The experimental scheme was essentially the same

as Figure 3-9a, but now wounds were harvested (either at 12 h or Day 7). Sections

were immunostained for Ly6G. The number of neutrophils at the wound site at 12
h post wounding, which was reduced in TSG-6 null mice relative to WT, was

significantly increased after one injection of rTSG-6 becoming similar to WT

(however, WT wounds receiving rTSG-6 showed some delay in neutrophil
recruitment) (Figure 3-9d). Likewise, the number of neutrophils observed in Day 7
wounds, ordinarily much higher in TSG-6 null wounds, was completely normalized
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to WT levels in mice receiving two rTSG-6 injections (Figure 3-9e). Thus, the
differential neutrophil recruitment observed in TSG-6 null wounds is reversible

when TSG-6 is restored in the skin.
a

Injection scheme,
5 sites per wound:
Wildtype

TSG-6 null

Relative size of 7 day wounds
p < 0.05

p < 0.05

Injections: Vehicle

Biopsy one subset
of wounds at 12 h

TSG-6 null + vehicle

rTSG-6

Biopsy another subset
of wounds at Day 7

TSG-6 null + rTSG-6

Injections: Vehicle

Figure 3-9. Introduction of rTSG-6 into TSG-6 null wounds rescues the delayed closure
and abnormal neutrophil recruitment.
(a) Schematics showing a time course and location of injections in WT and TSG-6 null wounds.
The black arrows indicate direction of injections. Wounds were injected with PBS only (vehicle)
or PBS with recombinant TSG-6 protein (rTSG-6) for both WT and TSG-6 null animals. (b)
Wounds were photographed and measured using IPLab imaging software to determine the
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open wound area, wound edge indicated by yellow dotted lines. (c) Wound sizes are
represented as the percentage of Day 0 area. Wound areas were significantly smaller for TSG6 null wounds receiving rTSG-6 compared to TSG-6 null vehicle wounds. (d) Neutrophil
staining of TSG-6 null vehicle control and TSG-6 null + rTSG-6 wounds at 12 hours post
wounding showed that the delay in recruitment was significantly rescued in null wounds
receiving rTSG-6 injections. (e) The exacerbated inflammatory response in TSG-6 null wounds
at Day 7 was significantly abrogated after rTSG-6 treatment. Statistical analysis was performed
using either Two Way ANOVA with Bonferroni correction or Kruskal-Wallis ANOVA on ranks.
(n), number of wounds; Scalebar= 100 um

3.4

Discussion

This study describes abnormal wound healing responses in mice lacking

TSG-6, the enzyme that catalyzes cross-linking of heavy chain proteins to
hyaluronan. Our overall findings show that relative to WT controls, TSG-6 null

wounds display (i) delayed wound closure, (ii) delayed neutrophil recruitment in
early wounds, (iii) exacerbated neutrophil recruitment in late wounds, and (iv)

polarization of wound macrophages toward a pro-inflammatory (“M1”) phenotype.
Reintroduction of recombinant TSG-6 can reverse both the delayed wound closure

and the abnormal neutrophil recruitment.
Our study was motivated by previous literature suggesting an important role
for TSG-6 in regulation of inflammation. In many cell and tissue types, TSG-6

expression is low or absent under normal conditions, but stimulated by pro-

inflammatory factors such as TNFa, interleukin-1 (IL-1), and LPS (Milner and Day
2003). Here we show that TSG-6 is constitutively expressed at low levels in

unwounded mouse skin, in agreement with earlier findings in human skin (Tan et
al. 2011). However, TSG-6 expression is greatly increased after wounding.

Similarly, HC-HA complexes are detectable in low amounts in normal skin and
become significantly elevated after wounding. HC-HA is completely absent in the

skin of TSG-6 null mice. Therefore, levels of TSG-6 appear to correlate with levels
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of its enzymatic product, HC-HA. Regarding wound inflammation, results reported
after injection of rTSG-6 or MSCs (which produce TSG-6 along with many other

factors) in other inflammatory models such as murine experimental arthritis

(Bardos et al. 2001), myocardial infarction (Lee et al. 2009), DSS-induced colitis
(Sala et al. 2015), and rabbit ear wounds (Wang et al. 2015), indicated that TSG-

6 might have an anti-inflammatory role, resulting in decreased disease activity

and/or improved recovery. In accordance with these studies, we found that
absence of endogenous TSG-6 is deleterious to wound healing whereas

restoration of the protein through direct dermal injection of rTSG-6 into TSG-6 null

mouse wounds restored normal wound healing, at least in terms of the parameters
evaluated here.
Beyond identifying a new wound-delay phenotype, our study provides

several insights about inflammation and TSG-6 in wounds. Total loss of TSG-6
results in exacerbated pro-inflammatory effects in healing wounds. As a brief
review, wounding initiates the release of multiple proinflammatory factors that
stimulate local recruitment of neutrophils and monocytes into the wound bed

(Martin and Leibovich 2005; Singer and Clark 1999; Wang 2018). Neutrophil

recruitment starts as early as 4 h post-wounding and plateaus around 3 days (Kim

et al. 2008). Studies in other models in which rTSG-6 protein was injected into
inflamed tissue revealed a decreased inflammatory response, including reductions

in pro-inflammatory cytokines and neutrophil infiltration (Beltran et al. 2015; Kim et
al. 2014a; Oh et al. 2010); absence of TSG-6 on the other hand led to increased

neutrophil infiltration (Szanto et al. 2004).
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Interestingly, in our TSG-6 null wound model the neutrophil recruitment

response appears to be biphasic. At early timepoints (12 and 24 h post-wounding),
neutrophils are significantly lower in TSG-6 null wounds than in WT wounds. To
explain this, we postulate an interaction between neutrophils and HC-HA on the

endothelial glycocalyx. It is known that the luminal side (endothelium) of blood
vessels is lined with an HA rich glycocalyx (Reitsma et al. 2007; Shakya et al.

2015), which we hypothesize under wound conditions becomes decorated with

HC, forming HC-HA complexes. Because leukocytes bind more avidly to HC-HA
complexes than to non-complexed HA (Lauer et al. 2014; Zhuo et al. 2006), HC-

HA should facilitate neutrophil attachment within small vessels in the wound bed

in WT wounds. Thus, the absence of HC-HA in TSG-6 null wounds should delay

neutrophil recruitment in early wounds. However, in later wounds, mechanisms of
neutrophil recruitment appear to be different since there is a relatively higher

number of neutrophils in TSG-6 null wounds as compared to WT. The excessive
levels of pro-inflammatory TNFa in TSG-6 null wounds may be one contributor to

neutrophil overabundance especially at Day 7 where levels of TNFa and
neutrophils are significantly higher in TSG-6 null wounds. TNFa elevation in TSG-

6 deficient mice might occur via several mechanisms, e.g. through feedback

inhibition pathways that become de-repressed upon loss of TSG-6, or via the
action of cytokines released by incoming macrophages that stimulate cells in the
wound bed to synthesize TNFa. Regardless of the recruitment mechanism,

excessive neutrophil activity has been tied to delayed wound healing (Kim et al.
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2008; Wilgus et al. 2013), and is therefore a likely contributor to the aberrant wound
healing observed in TSG-6 null mice.

Macrophages, the other major inflammatory cell type in wounds, remove

apoptotic neutrophil debris and also secrete pro-inflammatory and anti
inflammatory cytokines, depending upon the particular macrophage phenotype
(Koh and DiPietro 2011; Larouche et al. 2018; Wilgus et al. 2013). Although we
found no significant difference in the absolute number of macrophages in TSG-6

null versus WT wounds, we did determine that macrophages in TSG-6 null wounds

were skewed towards an M1 phenotype. This is in agreement with previous studies
showing that TSG-6 and immobilized HC-HA complexes can drive macrophages
to a more anti-inflammatory phenotype (Ferrer et al. 2017; He et al. 2013; Mittal et
al. 2016), and that TSG-6-producing MSCs can lower proinflammatory marker

expression and increase anti-inflammatory M2 macrophages in a colitis model

(Song et al. 2017). From several lines of evidence, including the fact that M2
macrophages are known to promote tissue repair, and that M1 macrophages are

greatly increased in chronic wounds such as diabetic ulcers, it is becoming clear
that controlled regulation of macrophage phenotype is critical for proper wound
healing (Hesketh et al. 2017a; Khanna et al. 2010; Krzyszczyk et al. 2018). Thus,

we conclude that TSG-6 plays a crucial role in regulating macrophage phenotypes

during cutaneous wound healing and this dysregulation in M1/M2 ratio in null
wounds could be contributing to aberrant healing.
An additional factor to mention, because it could potentially contribute to the

observed phenotypes, is an ability of TSG-6 to regulate chemokine function. As
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shown by Dyer et al., TSG-6 can regulate chemokine availability by competitive
binding to various chemokines and/or sulfated GAGs in the ECM (Dyer et al. 2016;

Dyer et al. 2014). Absence of TSG-6 might interrupt some of these interactions
and depending upon which cytokines are affected, could influence neutrophil

migration. This possible mechanism would make an interesting subject for future
investigation.

A strength of the current study is that TSG-6 restoration (rTSG-6 injection
into TSG-6 deficient wounds) was shown to normalize wound closure and
neutrophil recruitment. These results unambiguously establish that the defects
observed in TSG-6 null mice result from loss of TSG-6 protein. Interestingly, while
reintroduction of rTSG-6 into TSG-6 null wounds reversed the wound delay and

neutrophil recruitment defects, addition of rTSG-6 into normal WT wounds
worsened both of these phenomena. Apparently, tight regulation of TSG-6 is

critical for proper wound healing, and either excessive or insufficient amounts are

deleterious.

In summary, loss of TSG-6 leads to abnormal pro-inflammatory changes
and is detrimental to wound healing, whereas a regulated amount of TSG-6 is
crucial for a normal inflammatory response and proper wound closure. While more

studies are needed to fully elucidate the mechanisms behind the phenotypes

observed, our study provides important groundwork for understanding the role of
endogenous TSG-6 in cutaneous wound healing.
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3.5

Limitations
Following are some limitations of the methodologies involved in this study.

•

The wound protocol described required sacrificing of the mice after each time
point post wounding for wound collection, making it impossible to perform

linear study. An alternative could be developing neutrophil specific GFP
tagged WT and TSG-6 null mice and follow neutrophil recruitment post
wounding in-vivo using an appropriate imaging system.
•

The mouse wound closure study performed may have been affected by the
contraction due to mouse skin mobility, resulting in uneven closure pattern. To

avoid this, splints could be used to prevent the contraction due to skin mobility
and thus avoid the effect of this variable in wound closure result.
•

All the attempts to double stain the wound sections for pan macrophage
marker, F4/80, and any of the M1 or M2 markers, were unsuccessful. Since

this could provide a more conclusive result about differences in macrophage
phenotype polarization between WT vs TSG-6 null wounds, additional effort to
find combinations of pan-marker and M1/M2 markers that could be double

stained could

be made. Alternatively, different immunohistochemistry

conditions that will make this happen with the available markers could be tried.
•

For flow cytometric analysis of macrophage phenotype more than one M1/M2

marker each is desirable. However, this could not be attained here because
of the cell number constraint. To include more M1/M2 markers, the amount of

starting tissue material could be increased, which means more than 8 wounds

(> 2 animals) per sample.
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CHAPTER IV

ISOLATION OF SINGLE CELLS FROM CUTANEOUS WOUNDS FOR FLOW
SORTING AND FLOW CYTOMETRIC ASSESSMENT OF MACROPHAGES

4.1

Introduction

The intricate process of skin wound healing is broadly divided into three
overlapping phases- a) inflammation, b) tissue formation, and c) tissue remodeling

(Singer and Clark 1999). Each of these phases constitutes multiple events
coordinated by various cells, cytokines, chemokines, growth factors, and enzymes.
Macrophages are an important inflammatory cell type regulating wound healing.
These cells are known to regulate neutrophil recruitment and clearance during the
early stage of inflammation, as well as the activation of fibroblasts and endothelial

cells during the later phases of tissue formation and remodeling (Eming et al. 2007;

Koh and DiPietro 2011). Macrophages fulfill their roles through controlled
production of pro- and anti-inflammatory cytokines such as tumor necrosis factor
(TNF)-a, interleukin 1 (IL-1), and interleukin 10 (IL-10), and growth factors such as
the transforming growth factors TGF-a and TGF-b, platelet-derived growth factor
(PDGF), and vascular endothelial growth factor (VEGF). Based upon the cytokines

that they produce and the functions they perform, macrophages have been
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categorized into two main phenotypes, classically activated/pro-inflammatory (M1)

and alternatively activated/ anti-inflammatory (M2) (Hesketh et al. 2017b; Martinez
and Gordon 2014). Studies show that controlled regulation of the M1/M2 ratio is
critical for the proper and timely healing of wounds. For example, in chronic

wounds such as diabetic ulcers, more macrophages are of the M1 kind than in
normal wounds (Hesketh et al. 2017b; Krzyszczyk et al. 2018). In order to devise
new therapies to enhance wound repair, a greater understanding of the dynamics

of macrophage phenotype transition in normal vs. poorly healing/chronic wounds
will be critical. However, a major challenge to achieving that goal is the isolation of

intact macrophages (or other pure populations of cells such as neutrophils or
lymphocytes) from wounds for their subsequent analysis.

Here, we present an optimized version of a method described by Wilson et
al. (Wilson, Fathke and Isik, 2001) to prepare single cell suspensions from murine

skin wounds for flow cytometry. As flow cytometric analysis and fluorescence-

assisted cell sorting (FACS) are sensitive and well-known techniques to analyze

specific cell population, we employed these methods for further characterization of
macrophages. As per our experience, even the smallest details, such as the type

and size of tubes used for centrifugation, and the centrifugation speed, are

important and can influence the number and quality of viable cells obtained for
analysis, sorting, and downstream applications. The current protocol has been

developed by compiling information from across many sources and optimizing the
protocol for our purpose. The four major points identified and were optimized, that

were found to be critical for success, have been highlighted in blue boxes within
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the protocol. Our methodological description provides a well-defined protocol to
isolate cells from full-thickness cutaneous wounds, stain these cells for the

hematopoietic cell marker CD45 and the macrophage pan-marker F4/80, and to
analyze the cells by two different approaches, namely FACS for RNA analysis (A)
and flow cytometric analysis (B).

The method is described in three steps. Steps 1 and 2 are mostly similar for
the two analytical approaches (Analytic Method A and Analytic Method B) with
occasional differences which have been emphasized. Flow cytometric analysis
requires additional steps relative to cell sorting, so Step 3 has been divided into

two sections.
4.2

Method details

4.2.1 Step 1: Wounding and wound collection

Materials and reagents
•

Dulbecco’s Phosphate Buffered Saline (PBS, 1X) (Thermo Fisher Scientific,

Cat# 14190250, Waltham, MA, USA)
•

Ethanol, 70%

•

Ketamine and xylazine for anesthesia. (This will vary, depending upon your

institution’s animal protocol. We use Ketamine (100 mg/kg) and Xylazine (10

15 mg/kg) delivered intraperitoneally.
•

Forceps (Roboz, Cat# RS-5130, Gaithersburg, MD, USA)

•

Hair clipper (Wahl Clipper Corp., Model# 9962, Sterling, IL, USA)
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• Skin biopsy punch, disposable 5mm (Acuderm Inc., Cat# P550, Fort

Lauderdale, FL, USA)
• Heat lamp or Slide warmer

Procedure for Step 1
Notes:
a)

C57BL/6J mice were obtained from JAX Laboratories (Bar Harbor, ME). Mice

were maintained per guidelines of the American Association for the
Accreditation of Laboratory Animal Care. All procedures were approved by our

hospital’s Institutional Animal Care and Use Committee (IACUC).
b)

Male and female mice, 8-10 weeks of age, were used for wounding.

Shaving:
1-1.

Put mice under light anesthesia and shave the fur from two-thirds of the

dorsal skin, from below ear-level to the mid-back. Allow the mice to recover from
anesthesia in a warm environment.

Wounding:
1-2.

Inject an approved dose of anesthetic and disinfect the shaved skin area

with 70% ethanol.
1-3.

To make full thickness excisional wounds, pinch the dorsal shaved skin at

midline to make a large fold. Lay the mouse down on the surgical table laterally,
with the right side (right ear of the mouse) facing up, and the folded skin pulled far
away from the body. Press the skin biopsy punch through the folded skin to create

two clean wounds, located about a centimeter (1 cm) below the head and 1 cm
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apart. Similarly, using a new biopsy punch, make a second set of wounds 1 cm
caudal to the first set (Figure 4-1).

Figure 4-1. Wounds on the shaved back of a mouse.
Using 2 punch biopsies, make 4 wounds per mouse.

1-4.

Let the mice recover in a warm environment (under a heat lamp or on a

slide warmer in a cage). After wounding, each mouse should be housed
individually and monitored until collection day.
Wound collection:
1-5.

At Day 7 post-wounding (or at a different timepoint as needed), under deep

general anesthesia, harvest the entire wound area plus ~2 mm rim of unwounded

skin. Store the collected tissue on wet ice during this process, in a labeled
container such as the lid of a 60 mm tissue culture plate.
1.6.

Once all the wounds are collected, euthanize the mice.

4.2.2 Step 2: Tissue Digestion and single cell preparation

Materials and reagents
•

Collagenase, Type 1 (Worthington, Cat# LS004196, Lakewood, NJ, USA)

•

Dispase II (Roche Diagnostics, Cat# 04942078001, Indianapolis, IN, USA)

•

DNase I (Worthington, Cat# LS002060)
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•

Dulbecco’s Phosphate Buffered Saline (PBS, 1X) (Thermo Fisher Scientific,
Cat# 14190250)

•

EDTA disodium salt (Thermo Fisher Scientific, Cat# BP120)

•

Fetal Bovine Serum (FBS), Heat-inactivated (Gibco™, Thermo Fisher

Scientific, Cat# 10082139)
•

Fixation/Permeabilization Solution Kit with BD GolgiPlug™ (BD Biosciences
Cat# 555028, San Jose, CA, USA); This is NOT REQUIRED if doing FACS

sorting only
•

Flow Buffer (3% FBS and 0.1 mM EDTA in PBS)

•

G418 Sulfate antibiotic (Corning, Cat# 61-234-RG, Corning, NY, USA)

•

Hank’s buffered salt solution (HBSS, 1X) (Thermo Fisher Scientific, Cat#
14175079)

•

Trypan Blue solution (Lonza, Cat# 17-942E, Walkersville, MD, USA)

•

Falcon® 40-pm cell strainer (Corning, Cat# 352340)

•

Falcon® 15 ml polypropylene conical tube (Corning, Cat# 352097)

•

Falcon® 50 ml polypropylene conical tube (Corning, Cat# 352098)

•

Forceps (Roboz, Cat# RS-5130)

•

Hemacytometer (Bright-Line™, Sigma-Aldrich, Cat# Z359629, St. Louis, MO,

USA)
•

Kimwipes™ (Kimberly-Clark, Cat# 34120, Milsons Point, NSW, Australia)

•

Scissors (V. Mueller® Iris scissors, CareFusion, Cat# OP5526, McGaw Park,

IL, USA)
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•

Syringe filter, Fisherbrand® 25 mm, 0.2-pm (Thermo Fisher Scientific, Cat# 09719C)

•

Syringe, BD 60 ml (Becton Dickinson, Cat# 309653, Franklin Lakes, NJ, USA)

•

Centrifuge (5810 R, Eppendorf, Hauppauge, NY, USA)

•

Heat lamp or Slide warmer

•

Incubator shaker (C24, New Brunswick Scientific, Edison, NJ, USA)

Procedure for Step 2
Notes:
a) To have enough cells to process samples for flow cytometric analysis or FACS

sorting, wounds from 2 mice are pooled for each sample (total of 8 wounds per
sample).
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Optimization 1:

Here, we define the number of wounds and the amount of wound tissue required
per sample to have enough cells for flow cytometric analysis (as outlined) or

flow sorted macrophages to investigate M1/M2 polarization. Initially two wounds
were made per mouse, however, cell yields were sub-optimal. For optimum use
of available animals, 4 wounds per mice were made instead of 2 wounds (Figure
1). Eight wounds from 2 mice were pooled to have enough starting tissue per

sample.

Figure 1. Instead of two wounds per animal (a), four wounds were made per animal
(b) for flow cytometry purposes.

b) Keep the tissue pieces and the cells on wet ice (or at 4 °C) at all times, unless
otherwise stated.

c) Prepare 500 ml of Flow Buffer and store it at 4 °C (or on ice) at all times. This

buffer will be used for all washing and incubation steps unless otherwise
mentioned.

Dispase digestion:

76

Weigh wound tissue, then rinse one time in 70% ethanol and one time in 1X

2-1.

PBS. Dab tissue with a Kim-wipe to remove remnant PBS. On average, four 7-day
wounds from one mouse weighs about 175 mg.

Prepare dispase digestion buffer in HBSS by adding Dispase II at 1 mg/ml,

2-2.

G418 at 10 mg/ml, and 3% FBS. Filter using a 0.2-pm syringe filter and a 60 ml
syringe. A Stericup vacuum filtration system with a 0.22 um pore size (Millipore,

Cat# S2GPU02RE, Burlington, MA, USA) can be used in processing a bigger

volume. Prepare this buffer fresh every time.

Each milligram of wound tissue will require 20 pl of the dispase digestion

2-3.

buffer. For each sample (8 wounds), aliquot the required amount of the dispase

digestion buffer into a 50 ml polypropylene conical tube on wet ice. Two points to
note:

• It is important to use polypropylene conical tube (and not polystyrene
dishes) to avoid the released cells from adhering to the container.

• We use 50 ml conical tubes, even though the total volume is generally less
than 10 ml because it makes it easier to remove tissue pieces for the next

step.

2-4.

Using forceps and scalpel, cut tissues into 2-3 mm2 pieces and put them in

the tubes with dispase buffer. Do this on wet ice. Incubate at 4 °C overnight (No

shaking required).
2-5.

The following step is only for flow cytometric analysis. For the last two hours

of dispase digestion, add BD GolgiPlug™ from the Fixation/Permeabilization

solution kit to each sample, at a concentration of 1 pl/ml of digestion buffer.
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Optimization 2:

Here, we modified the addition of GolgiPlug™ to 2 hours before stopping the
dispase digestion step for flow cytometric analysis. This helped in retaining the

secretory cytokine (for example, TNFa in this case) inside the Golgi body in
cells while also preventing cell death from long term exposure to GolgiPlug™.

Collagenase digestion:

2-6.

Prepare collagenase digestion buffer in HBSS by adding Collagenase I at

1 mg/ml, G418 at 5 mg/ml and DNase I at 75 U/ml. Filter using a 0.2-pm syringe
filter and a 60 ml syringe. Again, a Stericup vacuum filtration system with a 0.22

um pore size, can be used in processing a bigger volume. Prepare this buffer fresh
every time; this can, however, be prepared a day earlier and stored at 4 °C.

2-7.

If doing flow cytometry analysis,

add

BD

GolgiPlug™

from the

Fixation/Permeabilization solution kit at 1 pl/ml to the filtered collagenase digestion
buffer mix above.
2-8.

Each milligram of wound tissue requires 80 pl of the collagenase digestion

buffer. For each sample, aliquot the required amount of the collagenase digestion

buffer into a labeled 50 ml conical tube at room temperature. Using forceps,
transfer tissue pieces from the dispase to the collagenase digestion buffer.
Incubate for 2 h at 37 °C with shaking at 95 rpm in an incubator shaker. Save the

remaining dispase buffer, which will contain a population of cells released from the

first digestion step, on ice.

2-9.

After incubation, combine cell suspensions from the dispase and

collagenase digestions and filter through a 40 pm cell strainer into a new 50 ml
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conical tube. Use 4-5 ml of Flow Buffer to rinse both tubes and pass this through

the cell strainer.
2-10. For centrifugation, divide the filtered cell suspension into several 15 ml

Falcon tubes, about 10-12 ml in each (Figure 4-2). Each sample may require 5 or
more tubes. The rationale here is that under the centrifugation conditions required

(see below), cells fail to form nice pellets in 50 ml tubes when large volumes are
used, and many cells are lost in the process. If you still prefer to use 50 ml tubes
instead of 15 ml ones, limit the volume in each tube to 10 ml.

Figure 4-2. Schematic for step 2-10.
Schematic showing the transfer of filtered cell suspension from one 50 ml conical tube to
multiple 15 ml conical tubes for centrifugation, as described in Step 2-10.
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Optimization 3:

Single cell suspensions obtained after dispase and collagenase digestions were
transferred to 15 ml tubes for better centrifugation. As shown in the figure below,

the cells did not form a proper pellet when centrifuged with large volumes in 50
ml conical tubes (Figure 2a). When centrifuged in 15 ml tubes, the cells formed
a nice pellet as desired (Figure 2b).

Figure 2. Use of appropriate tube sizes was found to be critical during centrifugation
to keep the cells intact and form a proper cell pellet.
Shown on the left is a 50 ml conical tube with a poorly formed pellet (a), while shown on
the right is a 15 ml conical tube with a clean, properly formed cell pellet (b).

2-11. Centrifuge at 350 x g for 10 min at 4 °C.
2-12. Being careful not to disturb the cell pellet, remove the supernatant using a

vacuum aspirator or pipettor, leaving about 1 ml.
2-13. Add 3 ml of Flow Buffer to the cell pellet and resuspend using a 10 ml pipet.

Centrifuge at 350 x g for 10 min at 4 °C.
2-14. Again, remove the supernatant with a vacuum aspirator, leaving about 500

ul of supernatant.
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2-15. Resuspend cell pellets in 1 ml of Flow Buffer per tube, then combine the

cell suspensions into a single 15 ml conical tube and pipet to mix well. Count live
cells under hemacytometer.

Assessment of viability of the single cell suspension: Combine 10 ul of well-mixed

cell suspension and 10 pl of Trypan Blue solution. Pipette 10 pl of this mix onto a
hemacytometer. Incubate for 2 min and count the unstained (viable) cells. We

typically obtain an average of 10 million live cells per sample (8 wounds) with >97%

viability.
Note: It is normal to see some debris along with single cells in the mixture under

the microscope.

4.2.3 Step 3: Cell staining with fluorophore markers for FACS sorting or flow

cytometric analysis
For analysis of cells by flow sorting (where cells are collected), or by

cytometric analysis (in which cells are analyzed but ultimately discarded), the initial
steps are the same. Thus, Steps 3-1 to 3-13 below are the same for both
approaches. After that, the procedures diverge. Section A (Steps 3-14 to 3-22)
contains procedures unique to FACS sorting of macrophages, while Section B

(Steps 3-23 to 3-39) contains instructions designed for flow cytometric analysis.

Materials and reagents
The following four antibodies, fluorophore-tagged:
^

FITC anti-mouse CD45 antibody (BioLegend, Cat# 103107, San Diego, CA)
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^

PE/Cy5 anti-mouse F4/80 antibody (BioLegend, Cat# 123111 )

^

Brilliant Violet 650™ anti-mouse TNFa antibody (BioLegend, Cat# 506333)

^

PE anti-mouse Arginase-1 antibody (Novus, Cat# IC5868P, Centennial, CO,

USA)
Reagents and materials, as follows:
•

AbC™ Total Antibody Compensation Bead Kit (Thermo Fisher Scientific, Cat#

A10497)
•

Fixation/Permeabilization Solution Kit with BD GolgiPlug™ (BD Biosciences
Cat# 555028); NOT REQUIRED if only doing FACS sorting

•

LIVE/DEAD™ Fixable Blue Dead Cell Stain Kit (Thermo Fisher Scientific, Cat#
L23105)

•

Mouse BD Fc Block™, Purified Rat Anti-Mouse CD16/CD32 (BD Biosciences,
Cat# 553141)

•

TRIzol™ Reagent (Thermo Fisher Scientific, Cat# 15596018)

•

1.7 ml microcentrifuge tubes (Denville, Cat# C2170, Saint-Laurent, QC,

Canada)
•

2 ml microcentrifuge tubes (USA Scientific, Cat# 1620-2700, Ocala, FL, USA)

•

CellTrics® filters, 30 pm (Sysmex Partec GMBH, Cat# 04-004-2326, Görlitz,
Germany)

•

Fisherbrand® serological pipets (Thermo Fisher Scientific, 5 ml, Cat# 13-67811D, and 10 ml, Cat# 13-678-11E)

•

Centrifuge 5415 D (Eppendorf) [store in a cold-room, at 4 °C, for cold
centrifugation]
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Procedure for Step 3
Notes:
a) Treat the live cells as gently as possible. Use 5- or 10- ml serological pipets to

mix cells in centrifuge tubes or careful pipetting using 1 ml pipette in

microcentrifuge tubes. Do not vortex live cells.
b) The working concentrations for all antibodies used in this protocol are based

on optimization done for our tissue/cell type. Optimization is done by testing for at

least 6 serial dilutions starting with a concentration recommended in the antibody

datasheet and tested by flow cytometry. The working concentrations for the
antibodies are as follows: anti-CD45 at 1:200, anti- F4/80 at 1:80, anti-Arginase-1

antibody at 1:10 and anti-TNFa antibody at 1:40.
c) Having a proper set of controls is critical for successful flow cytometric analysis

as well as for FACS sorting. Control tubes and experimental tubes should be

treated in the same way, with the same number of washes and centrifugations. To
prepare control tubes with cells, mix aliquots of cell suspension from each sample
to achieve 1 million cells for each type of control. For example, if you have 4
samples resuspended at 1 million cells/ml, take 250 pl from each sample tube and
put in a 1.7 ml microcentrifuge tube (Figure 4-3).
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Figure 4-3. Schematic showing preparation of control tube with cells.
To prepare each control tube with cells, mix aliquots of cell suspension from all samples into
a 1.7 ml tube.

d) Table 4-1 (below) gives a list of controls required for the FACS sorting of

macrophages. Table 4-2 gives a list of controls required for flow cytometric
analysis of M1/M2 macrophages. Note that the AbC™ Compensation beads were

used for antibody compensation controls for both techniques, except for Arginase-

1 antibody. Our Arginase-1 is a sheep-primary antibody and is not compatible with

the AbC™ beads kit, so cells were used instead.
Table 4-1.
Method A)

List of controls required for FACS sorting of macrophages (Analytical

(For further explanation of controls refer to Note c)

Fluorophore tagged markers
Tube #

J
x

Label

Live/Dead™
blue

CD45

F4/80

1

û

û

û

Unstained

2

ü

û

û

Live/Dead only

3

ü

ü

x

L/D + CD45

4*

x

ü

x

CD45 Comp.

5*

x

x

ü

F4/80 Comp.

= Marker added into tube
= Marker not added
= Compensation control with AbC™ compensation beads

84

Table 4-2. List of controls required for Flow cytometric analysis (Analytical Method B)

(For further explanation of controls, refer to Note c)
Fluorophore tagged markers

Tube#

Label

Live/Dead™
blue

CD45

F4/80

Arg-1

TNFa

1

x

x

x

x

x

Unstained

2

ü

x

x

x

x

Live/Dead only

3

ü

ü

x

x

x

L/D + CD45

4

ü

ü

ü

x

x

L/D + CD45 +
F4/80

5

ü

ü

ü

ü

x

FMO TNFa

6

ü

ü

ü

x

ü

FMO Arg-1

7**

x

x

x

ü

x

Arg-1 Comp.

8*

û

ü

x

x

x

CD45 Comp.

9*

û

x

ü

x

x

F4/80 Comp.

10*

x

x

x

x

ü

TNFa Comp.

= Marker added into tube
= Marker not added
*
= Compensation control with AbC™ compensation beads
**
= Compensation control with cells (unique to Arg-1)
FMO = Fluorescence minus one
J

x

e) Compensation beads were stained as outlined in the kit manual.

f) Centrifugation conditions for preparation of controls and samples: For 1.7 ml
microcentrifuge tubes, 400 x g for 5.5 min at 4 °C. For 15 ml conical tubes, 350 x
g for 10 min at 4 °C.
Optimization 4:

Limiting the number of centrifugations to twice instead of 3-times between steps
at the above-mentioned speed and duration throughout the protocol helped limit
the loss of cells during washing and subsequent pipetting.
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SHARED STEPS (common to FACS sorting and to Flow cytometry)

Staining with Live/Dead™ blue:

3-1.

For each sample from Step 2 (in 15 ml tubes), add Flow Buffer to adjust the

cell count to 1 million cells/ml.

3-2.

Prepare a 1 ml aliquot for unstained control (Tube# 1) into a labeled 1.7 ml

microcentrifuge tube (as outlined in Note c) and treat this tube similarly to the rest

of the cells. Remember to centrifuge/wash control tubes the same number of times
as the other tubes for the entire procedure. If doing flow cytometry analysis,
separate an additional aliquot for Arginase-1 compensation control (Tube# 7 in

Table 4-2).

3-3.

Stain cell samples in 15 ml tubes for dead cells using LIVE/DEAD™ Fixable

Blue Dead Cell Stain Kit as recommended in the user guide. Remember to bring

the vial of DMSO and a tube of reactive dye from the kit to room temperature before

using. Add 1 pl of reconstituted fluorescent reactive dye per 1 mL of cell
suspension.

3-4.

Mix well using a 10 ml pipet and incubate on ice for 30 minutes in the dark.

3-5.

After incubation, add 5 mL of Flow Buffer to each sample and centrifuge.

Remember to centrifuge control Tube# 1 (and Tube# 7 for flow cytometry analysis)
as well.

3-6.

Remove supernatant as before, leaving about 500 pl. Resuspend the pellet

in 6 ml of Flow Buffer (and control pellet in 1 ml of Flow Buffer) and then centrifuge
one more time.
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3-7.

Remove supernatants from 15 ml tubes as before, leaving about 250 ul.

(Resuspend control pellets in 1 ml Flow Buffer and place on ice).

Blocking Fc receptors and staining for fluorophore-tagged (extracellular)
antibody markers:
3-8.

Resuspend cell pellets in the 15 ml tubes at a concentration of 1 million cells

per 50 pl of Flow Buffer.
3-9.

Separate out a 50 pl total aliquot of cells for Live/Dead only control (Tube#

2) into a labeled 1.7 ml microcentrifuge tube. As explained in Note (c) above, the
control is prepared by mixing aliquots of cell suspension from all samples [that is,

if you have 4 samples, take 12.5 pl from each sample to prepare a control tube].
Add 50 pl of Flow Buffer to bring the volume to a total of 100 pl.

3-10. To the remaining cells in the 15 ml tubes, add 1 pg (= 2 pl) of Mouse BD Fc

Block™ per 50 pl of cell suspension and incubate for 5 min on ice in the dark.
3-11. During this incubation, prepare cell surface antibody mix as follows:

• For Live/Dead + CD45 control (control Tube# 3), prepare 50 pl of anti-CD45
antibody at 1:100 in Flow Buffer.

• For the remaining cells in 15 ml tubes, prepare a cocktail of anti-CD45
antibody at 1:100 and anti-F4/80 antibody at 1:40 in Flow Buffer. Prepare
50 pl of this mix per 1 million cells. Calculate the volume of the antibody
cocktail required as follows:

For example, if Sample A has 5 million cells and Sample B has 8 million

cells, the total volume of antibody cocktail required is: 50 x (5+8) = 650 pl.
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3-12. After incubation with Fc Block, separate an aliquot of 50 ul cell suspension
for Live/Dead + CD45 control (Tube# 3) into a labeled 1.7 ml microcentrifuge tube

by again mixing aliquots from all samples (as outlined in Note c).

3-13. Add antibody mix prepared in step 3-11 into the control Tube# 3 and the 15
ml tubes and incubate for 20 minutes on ice in the dark.

*** If you are doing Flow Cytometric Analysis, go to Section B (step 3-23).
Otherwise, continue to step 3-14 to perform FACS sorting of macrophages.
Optimization:

The effect of the major optimizations highlighted thus far is shown in the figure
below. Figure 3a represents the total number of cells before optimization
whereas Figure 3b shows the total number of cells after optimization. In the
latter, the number of cells were much higher which subsequently resulted in

obtaining higher number of macrophages for flow cytometric analysis or sorting.

Figure 3. After all the described optimizations, the percentage of cells retained at the
endpoint of flow cytometry was much higher (b) than before (a).
The gate was applied as shown to filter out the debris during analysis.
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Analytical Method A: FACS sorting for macrophages
Experiment
al Tube# B

Tube:

Control
Tube# 1

Control
Tube# 2

Control
Tube#
3

Control
Tube# 4

Control
Tube# 5

Experiment
al Tube# A

Contains:

Cells

Cells

Cells

Compen
sation
beads

Compen
sation
beads

Cells

Cells

Antibody
mix:

No
Antibody

No
Antibody

CD45

CD45

F4/80

CD45
F4/80

CD45
F4/80

Live/Dea
d Blue

No

Yes

Yes

No

No

Yes

Yes

Figure 4-4. Control and experimental tubes for FACS sorting.

3-14. During the incubation, transfer the remaining sample from 15 ml tubes into
as many (1.7 ml or 2 ml) microcentrifuge tubes for experimental samples,
irrespective of the cell number per sample tube.

3-15. After incubation, add 500 ul Flow Buffer to all microcentrifuge tubes, and
spin.

3-16. Remove supernatant using a 1 ml pipette, leaving about 50 pl. Resuspend
in 1 ml of Flow Buffer and centrifuge once more.

3-17. Remove supernatant carefully using a 1 ml pipette leaving about 50 pl.

Resuspend at 1 million cells per 100 pl of Flow Buffer and store in cold for FACS
sorting. Plan to sort these cells as soon as possible after staining.

Figure 4-4 depicts the tubes we need to have with all the applicable conditions by

the end of this process.
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FACS sorted cell collection:
Flow sorting was done using a BD FACSAria II sorter and BD FACSDiva
software (BD Biosciences) with assistance from personnel at Cleveland Clinic LRI

Flow Cytometry Core. Cells were sorted using a 100 um nozzle size at a low sheath

pressure of 20 psi.

3-18. Label 2 ml microcentrifuge tubes or 15 ml conical tubes as required to
collect the desired cell populations. For each experimental sample, we collected

two subsets of cell populations for RNA isolation, as follows:
• CD45+ (CD45 only positive) cells for control.
• CD45+ F4/80+ (CD45 and F4/80 double positive) macrophages.

3-19. Add 500 pl of TRIzol™ reagent into the labeled collection tubes before
loading them unto the sorter.

3-20. Right before sorting, filter the cell samples (controls and experimental's)
through CellTrics® 30 pm filters to remove any clumps.

3-21. After sorting, calculate the volume of cell suspension sorted into each tube
using a 1 ml pipette and add more TRIzol to bring the ratio of sort volume and

TRIzol to at least 1:3. Pipette up and down multiple times to lyse the cells and
homogenize well.

3-22. Store the homogenized sample on ice. When ready to isolate RNA, incubate
the homogenized sample for 5 minutes at room temperature and proceed with
RNA isolation following standard protocol.

90

• Note: The samples in TRIzol can be frozen at -20 °C if necessary, for later RNA
isolation. However, it is discouraged for this protocol as the number of sorted cells

is limited. See Method validation section below for further details.
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Analytical Method B: Flow cytometric analysis of M1/M2 macrophages
Experim
entai
Tube# B

Tube:

Control
Tube# 1

Control
Tube# 2

Control
Tube#
3

Control
Tube#
4

Control
Tube#
5

Control
Tube#
6

Control
Tube#
7

Control
Tube# 8

Control
Tube# 9

Control
Tube#
10

Experim
entai
Tube# A

Contains:

Cells

Cells

Cells

Cells

Cells

Cells

Cells

Compen
sation
beads

Compen
sation
beads

Compen
sation
beads

Cells

Cells

Antibody
mix:

No
Antibody

No
Antibody

CD45

CD45
F4/80

CD45
F4/80
Arg-1

CD45
F4/80
TNFa

Arg-1

CD45

F4/80

TNFa

CD45
F4/80
Arg-1
TNFa

CD45
F4/80
Arg-1
TNFa

Live/Dea
d Blue:

No

Yes

Yes

Yes

Yes

Yes

No

No

No

Yes

Yes

Yes

Figure 4-5. Control and experimental tubes for flow cytometric analysis.
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Fixation/Permeabilization:

3-23. After incubation with cell surface antibody mix in Step 3-13 above, add 2 ml
buffer to 15 ml tubes and centrifuge.

3-24. Remove supernatant carefully using a 1 ml pipette, leaving about 100 pl.

Resuspend in 3 ml buffer and centrifuge again.
3-25. Remove supernatant and resuspend cells at a concentration of 1 million
cells per 100 pl of Flow Buffer.
3-26. Add 250 pl of Fixation/Permeabilization solution per 1 million cells, mix by
pipetting, and incubate for 20 minutes on ice in the dark.
3-27. During the incubation, prepare 1 X Perm/Wash buffer from the 10X BD

Perm/Wash buffer in the Fixation/Permeabilization Solution Kit as recommended.
After incubation with the fixation/permeabilization buffer, add 500 pl of 1 X

Perm/Wash buffer per 1 million cells, mix and centrifuge.
3-29. Remove supernatant using 1 ml pipette, resuspend in 1 mL BD Perm/Wash

buffer and centrifuge again.
3-30. Remove supernatant and resuspend the cell pellets at 1 million cells per 50

pl of Flow Buffer.
3-31. Prepare an aliquot of 50 pl cell suspension for Live/Dead + CD45 + F4/80

control (Tube# 4) as before in Step 3-9.
3-32. To the remaining sample tubes, add 1 pg (= 2 pl) of Mouse BD Fc Block™
per 50 pl of cell suspension and incubate for 5 minutes in the dark at room

temperature.
3-33. During this incubation, prepare the intracellular antibodies as follows:
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• For FMO TNFa control (Tube# 5), prepare 50 ul of anti-Arginase-1 antibody
at 1:5 in Flow Buffer.

• For FMO Arg-1 control (Tube# 6), prepare 50 pl of anti-TNFa antibody at
1:20 in Flow Buffer.

• For Arg-1 comp. control (Tube# 7), prepare 50 pl of anti-Arginase-1

antibody at 1:5 in Flow Buffer.
• For the experimental tubes, prepare a cocktail containing anti-Arginase-1

antibody at 1:5, and anti-F4/80 antibody at 1:40 in Flow Buffer. Prepare 50
pl of this mix for as many experimental samples as required. This can be
simply calculated as: (Number of samples) x 50 pl.

Refer to Table 4-2 and/or Figure 4-5 for more information about the controls.

3-34. After incubation with Fc Block, prepare aliquots of 50 pl cell suspension (~1
million cells ideally) for FMO control tubes (Tube# 5-6) into labeled 1.7 ml

microcentrifuge tube as before in Step 3-9.

3-35. From the remaining cells, prepare experimental samples. Transfer one 50
pl aliquot (1 million cells) from one 15 ml tube to one 1.7 ml microcentrifuge tube.
Note: It is important to have an equal number of cells in each experimental sample.

Staining for intracellular markers for M1 and M2:

3-36. Add 50 pl of intracellular antibody mix prepared in step 3-33 to respective

control tubes and experimental tubes. Incubate for 25 minutes in the dark at room
temperature

3-37. During this incubation, prepare the compensation controls with beads
(Tube# 8, 9 and 10). Stain the beads as outlined in the kit manual.
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3-38. After the incubation, add 500 ul of Flow Buffer to all tubes and centrifuge @
900 x g for 5.5 minutes at room temperature. Resuspend cell pellet in 1 mL buffer
and centrifuge once more.

3-39. Resuspend cell pellet in 100 pl of Flow Buffer and store in dark until ready
for flow cytometry analysis.

4.3

Method validation

4.3.1 Validation of FACS sorting
Single cells were isolated from wounds as described. After staining, the
cells were FACS sorted. The gates for cell sorting were determined by evaluating

events from the control tubes and experimental samples as depicted in Figure 46a-f. Also shown are representative dot plots for different controls and an

experimental sample. During sorting, two groups of cells were collected directly in

TRIzol reagent. For n= 10 samples (8 wounds/ sample), approximately, an
average of the following number of cells were obtained:
•

55,400 CD45+ F4/80+ double positive macrophages

•

85,900 CD45+ only positive cells
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Figure 4-6. Representative dot plots for FACS sorting.
(a) Cell debris were excluded using the forward- and side-scatter gates from unstained control
(Tube# 1); (b) Unstained (Tube# 1) and Live/Dead only (Tube# 2) controls were used to filter
out dead cells.
Representative dot plots for (c) Unstained control (Tube# 1), (d) Live/Dead only control (Tube#
2), (e) Live/Dead+CD45 control (Tube# 3) and (f) and (g) Experimental samples.
Control tubes #4 and #5 were used to remove any spillover between the fluorescence channels
(Image not shown)
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When ready for RNA isolation, the homogenized samples stored in ice (or

thawed in ice for frozen samples) were incubated at room temperature for 5 min.

RNA was isolated as per the standard TRIzol RNA isolation protocol using
chloroform. To enhance the amount of RNA obtained, the Phase Lock Gel™

Heavy tubes (VWR, Cat# 10847-802, Radnor, PA, USA) were used for better
separation of the aqueous layer from the interphase and organic phase during
centrifugation. The RNA pellets obtained after isopropanol seperation were
washed twice with 75% ethanol and resuspended in RNase free water.

Quantification was done using a NanoDrop 2000 spectrophotometer (Thermo
Fisher Scientific) and complementary DNA (cDNA) were prepared using 200 ng of

RNA each.
To validate the specificity of the sort, we performed quantitative PCR
(qPCR) assay for the Adgre1 (adhesion G protein-coupled receptor E1) gene that
encodes for the F4/80 protein. TaqMan primers for Adgre1 (Thermo Fisher

Scientific, Cat# 4331182) along with 18S (Cat# 4333760F) as the endogenous

control were used for this purpose. We evaluated 10 samples for the CD45+ only
positive group, among which half the samples had Ct (cycle threshold) value
undetermined indicating that the target gene was too low in these samples to be

detectable. The Ct values for the remaining 5 samples were analyzed in
comparison to Ct values for the CD45+ F4/80+ double positive samples (n= 6) to
calculate the relative expression of Adgre1 gene in the two groups. Using delta
delta Ct (DDCt) method, we found that Adgre1 gene expression was more than 94
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-fold higher (p-value <<0.0001) in the double positive macrophage group, thus
indicating a successful sort (Figure 4-7).

CD45+ F4/80+
macrophages

CD45 only cells

Figure 4-7. Evaluation of Adgre1 expression for the two FACS sorted cell populations.
The gene encoding macrophage specific marker protein F4/80 is expressed at least 75 -fold
higher in the double positive macrophage cell population than the CD45 only positive control
cell population. Statistical analysis was performed using Student’s t-test. n, number of
samples.

4.3.2 Validation of flow cytometric analysis

Single cells were isolated from full thickness skin wounds and stained for

cell surface markers followed by intracellular markers after fixation, as described.
Flow cytometry assay was done using BD LSR Fortessa cell analyzer and BD

FACSDiva software (BD Biosciences) at the Cleveland Clinic LRI Flow Cytometry
Core with assistance from the core personnel. Gating hierarchy was determined

as per standard flow analysis using the unstained, live-dead blue, and
fluorescence minus one (FMO) controls. Analysis was performed using Flow Jo.

The gating hierarchy for flow analysis is shown in Figure 4-8a - d. Using gating,
dead cells and debris were excluded along with cell clumps. For further analysis,

98

only cells expressing high intensity of CD45+ F4/80+ signals, which should be

macrophages, were selected as shown by the gate in Figure 4-8d.

Figure 4-8. Gating strategy for flow cytometric analysis and representative dot plots for
experimental samples.
Macrophages analyzed from wounds at 5 days post wounding. (a) The smaller cell fragments
and debris are dropped from analysis using FSC/SSC (b) All non-single cells or cells clumps
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are gated out using FSC-A/FSC-H (c) The live gate removes the Live/Dead blue positive dead
cells and only live cells are considered for further analysis (d) Cells double positive for CD45
and F4/80 are gated as macrophages for M1/M2 phenotype characterization (e and f)
Representative dot plot quadrants from 2 separate experiments with the percentage of cells in
each quadrant outlined.

Figure 4-8e and f depict two representative dot plots for the experimental

samples after all the gating. Each dot in either of these plots represents a
macrophage which was further analyzed for the expression of the chosen M1

marker, TNFa, and the M2 marker, Arg-1. Preliminary analysis of macrophage

phenotype in our experiment show that most of the macrophages at the 5-day time

point analyzed here are either high positive for Arg-1 (Arg-1+) or double negative/

low positive for both Arg-1 and TNFa (Arg-1- TNFa-). Only a small fraction of the
cells is high positive for TNFa (TNFa+), and a negligible portion of the cells are

high double positive (Arg-1+ TNFa+). Hence, many of the cells have not undergone
polarization at this time point after wounding although a higher percentage of cells

are of the M1 phenotype.

4.4

Summary

Here, we have provided a detailed protocol for the isolation of single cells
from cutaneous wounds with an emphasis on analysis of macrophages in

particular using FACS sorting and flow cytometric analysis. These should prove to
be very helpful techniques for the identification and functional assessment of

specific cell populations and even of individual cells. This method could be
extended to isolate other, different cell populations from wounds (such as
neutrophils or lymphocytes), and to assess their characteristics by employing

markers specific to the cell type of interest.
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4.5

Limitations
Following are some limitations of the methodologies involved in this study.

•

For flow cytometric analysis, due to cell number constraint, only one marker

each for M1 and M2 macrophage phenotypes could be used. However, as
M1/M2 is not an absolute phenomenon and the expression of these markers is
more transitional, a combination of 2 or more markers for each phenotype is
preferred. Thus, for a more conclusive result to determine any differences in

wound macrophage phenotype more markers could to be included. This

indicates that an additional amount of wound tissue will be required for flow

cytometric analysis.
•

Here, since whole wounds are used that consists of a substantial amount of
extracellular matrix, the protocol required rigorous digestion steps as

described. In the process, it is expected to have a lot of debris in the single cell
suspension used for antibody staining and further analysis. To avoid this, an
additional filtration step could be included to remove the debris as much as

possible from the cell suspension.
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CHAPTER V
IN-VIVO ASSESSMENT OF LEUKOCYTE ROLLING AND ADHESION UPON
CHEMICAL INJURY IN THE PRESENCE OR ABSENCE OF TUMOR

NECROSIS FACTOR-STIMULATED GENE-6 USING INTRAVITAL
MICROSCOPY

5.1

Introduction

The tumor necrosis factor-stimulated gene-6 (TSG-6), a 30-35 kDa protein

encoded by the TSG-6 gene, is stimulated upon exposure to pro-inflammatory
cytokines such as TNFa and IL-1, or lipopolysaccharide (LPS) (Lee et al. 1990;

Mittal et al. 2016; Wisniewski et al. 1996). The TSG-6 protein is predominantly

known to play an anti-inflammatory role through its ability to bind to different
ligands. TSG-6 is known to bind to matrix molecules such as sulfated and non

sulfated glycosaminoglycans (GAGs), matrix proteins such as heavy chains (HC)
from

inter-alpha-trypsin

inhibitor

(IaI),

fibronectin,

pentraxin-3,

and

thrombospondin-1, as well as immune regulating chemokines such as CXCL-8.
Binding to most of these molecules has been demonstrated to involve the Link
domain of TSG-6, while a few require the CUB domain (Day and Milner 2018).
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Neutrophils are known to be the first inflammatory cell type to reach sites of
inflammation (Rosales et al. 2017), and multiple studies have shown that TSG-6 is
involved in neutrophil recruitment. In an arthritic mouse model, mice lacking TSG-

6 (TSG-6 null) displayed an early and increased infiltration of neutrophils resulting

in a significantly greater rate of disease progression and severity compared to
wildtype (WT) mice (Lesley et al. 2004; Szanto et al. 2004). Conversely, addition

of recombinant TSG-6 (rTSG-6) into the inflammatory site has been demonstrated
to have a therapeutic effect in many disease conditions by modulation of neutrophil
recruitment. In a murine air pouch model of acute inflammation, injection of rTSG-

6 along with the inflammatory stimulus lead to a significant reduction in the number

of cells infiltrating the air pouch 4 hours after injection (Wisniewski et al. 1996).

Similarly, injection of rTSG-6 in a rodent model of gingival wounds resulted in less
inflammation and reduced expression of the neutrophil-related inflammatory

marker, myeloperoxidase (MPO), followed by early wound healing (Beltran et al.
2015). Moreover, studies in corneal injury models showed a decrease in neutrophil

infiltration after treatment with rTSG-6 compared to vehicle-only controls, along
with a reduction in corneal damage (Kim et al. 2014b; Oh et al. 2010).
Additionally, studies have shown that TSG-6 is produced by activated

mesenchymal stem cells (MSCs) under inflammatory conditions, providing an anti

inflammatory effect. In a peritonitis model, the infusion of MSCs caused a reduction
in the number of neutrophils reaching the inflammation site. This was attributed
partially to the effect of TSG-6 produced by activated MSCs on the resident
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macrophages, resulting in reduced CD44-dependent TLR2 and NF-kB signaling

(Choi et al. 2011).

Although TSG-6 is mostly demonstrated to have an anti-inflammatory
effect, a study by Swaidani et al. in a murine model of asthma provides a different
viewpoint. In the study, bronchoalveolar lavage fluid obtained from TSG-6 null mice
after induction

of pulmonary

inflammation

contained

significantly fewer

inflammatory cells, including a reduced number of neutrophils, compared to WT
littermates (Swaidani et al. 2013). This was accompanied by a decrease in the

quantity of the non-sulfated GAG, hyaluronan (HA), in the lavage fluid as well as
the lung tissue, indicating a role of pathological HA in creating the higher level of
inflammation in WT mice. This effect was also attributed to the absence of HC-HA
complexes (the product of HC and HA crosslinking mediated by the enzymatic

action of TSG-6), in TSG-6 null mice.

While all the above studies show that TSG-6 plays a role in inflammation

and recruitment of neutrophils into sites of injury or inflammation, there is still no

direct evidence to indicate that loss of TSG-6 affects the rolling and adhesion
behavior of neutrophils nor their rate of extravasation from blood vessels.
Therefore, in this chapter we attempted to address this question by employing

intravital microscopy for direct visualization of leukocyte rolling, adhesion, and

transmigration in-vivo, using a murine ear model of acute skin inflammation. The
model involved application of croton oil, a chemical irritant. Our main purpose was

to determine whether the absence of TSG-6 affects any of the component steps in
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the extravasation of neutrophils (rolling, adhesion/arrest, and transmigration) as
the neutrophils transition from the circulation into the chemically injured tissue.

5.2

Materials and Methods

5.2.1 Animals

C57BL/6J wild-type (WT) mice were obtained from JAX Laboratories (Bar
Harbor, ME). TSG-6 null mice, whose generation was described by Fulop et al.

(Fulop 2003), in C57BL/6 background was generously provided by Dr. Mark
Aronica in our institute. All mice were maintained per guidelines of the American

Association for the Accreditation of Laboratory Animal Care. All procedures were
approved by the Cleveland Clinic Institutional Animal Care and Use Committee.

5.2.2 Croton oil-induced ear inflammation
Mice (WT, or TSG-6 KO, age-matched male and female) were anesthetized
with isofluorane and chemical inflammation was induced as described by Coruzzi

et al. (Coruzzi et al. 2012) with some modification. Croton oil (Sigma-Aldrich, St.

Louis, MO) (2% in acetone) was topically applied on the inner surface of the left
ear (50 ul per ear) with a micropipette and cotton swab. An equal amount of
acetone was applied on the right ear as vehicle control. After the applications, the
mice were allowed to recover from the anesthesia and housed under optimum
conditions before proceeding to the next step. Croton oil application was staggered

by 1.5 hours between any two mice, to allow enough time to perform intravital

microscopy of both ears of each mouse.
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5.2.3 Validation of croton oil-induced inflammation
To validate the induction of inflammation, 4 hours after croton oil application,
a set of mice were euthanized by ketamine-xylazine anesthesia, followed by

cervical dislocation, and both the left and right ears were cut at the base and fixed
in Histochoice (Amresco, Solon, OH), followed by paraffin embedding. Using a

microtome, 5-micron thick sections were cut and stained for the neutrophil
granulocyte marker, myeloperoxidase (MPO). The sections were rehydrated and

incubated overnight at 4 °C with rabbit polyclonal anti-MPO antibody (Thermo
Fisher Scientific, Waltham, MA) at 1:100 dilution. Sections were then incubated

with Donkey anti-rabbit Rhodamine Red-X-conjugated secondary antibody

(Jackson ImmunoResearch, West Grove, PA) at 1:500 dilution, for 1.5 hour, and
mounted in VECTASHIELD mounting medium (Vector Laboratories, Burlingame,
CA). Images were captured using a Leica DM upright microscope (Leica

Biosystems).
5.2.4 Intravital microscopy

In-vivo labeling of leukocytes by intravenous injection of dyes
For visualization of leukocytes, the dye Rhodamine 6G (Sigma-Aldrich) was
used at 0.5 mg/kg body weight as described previously (Ichioka et al. 2007).

Rhodamine 6G is a membrane-permeable DNA fluorescent dye that stains

nucleated cells (Gal et al. 2005). Contrast enhancement of the intravascular space
was achieved by using Qtracker® 655 Vascular Label (Thermo Fisher Scientific,

Waltham, MA), which binds intravascular serum proteins such as albumin. At 4
hours after croton oil application, the mice were anesthetized with an
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intraperitoneal injection of Ketamine-Xylazine. A single injection containing
Rhodamine 6G (0.5 mg/kg body weight) and Qtracker® 655 (20 pl) in normal

saline, in a maximum total volume of 120 ul, was administered retro-orbitally (RO).
Intravital microscopy was started within 5 minutes of the RO injection.

Positioning of mice for microscopy
After the retro-orbital injection, the anesthetized mouse was placed on a

heated stage for microscopy as shown in Figure 5-1. The ear was positioned to lie

flat against a glass cover slip on the stage, and secured with tape.

Figure 5-1. Positioning of the mice for microscopy.
Mouse, lying on its side, was placed on a heated stage of the inverted microscope. The ear
was taped flat to a glass cover slip that sits above the objective lens. (The objective, located
beneath the stage, cannot be seen here).

Microscopy and video recording

A Leica DMi8 inverted microscope connected to a Leica TCS SP8 confocal
system (Leica Microsystems, Wetzlar, Germany) was used to record videos of

leukocyte behavior in vivo. A combination of lasers at 514 nm and 488 nm was
used for excitation of Rhodamine 6G and Qtracker 655, respectively. Wavelength

ranges of 526-600 nm for Rhodamine 6G, and 620-752 nm for Qtracker 655, were
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used for collectinion of the emitted light. Video recordings of 30 second duration,

from each of 2-4 vessels per mouse, were made using a 40X oil immersion lens.
Leica Application Suite X (LASX) (Leica Microsystems), running on the computer

connected to the confocal system, was used to control this process.
5.2.5 Analysis of leukocyte behavior

The recorded videos were analyzed offline using LASX. Leukocyte
behaviors of rolling or adhesion were defined as described in previous studies
(Ichioka et al. 2007; Jbeily et al. 2014). Briefly, a rolling leukocyte was defined as

a cell moving along the endothelial wall at a velocity much less than that of the
surrounding blood flow, and which interacted with the endothelial lining for only a

few seconds during the 30 second recording. An adherent leukocyte (or arrested
leukocyte) was defined as a cell that remained stuck to the vessel wall for the entire

duration of the 30 second video.
The number of rolling and adherent leukocytes was determined by
observing cell behavior within 100-um vessel segments, in small-caliber vessels
of a diameter between 10 to 50 um. Calculations of rolling and adhesion were
done as discussed by Gal et al. (Gal et al. 2005). Briefly, rolling cells were

quantified by counting the number of rolling cells in the 100 pm vessel length during
30 s, and expressing this as the number of rolling cells per minute per 103 pm of

vessel perimeter. Adherent cells were quantified by counting the number of

adhered cells in the 100 pm vessel length, and expressing this as the number of

adherent cells per 105 pm2 of vessel area.
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5.2.6 Statistical analysis
Numerical data were expressed as Mean ± SEM. All statistical analyses

were performed using SigmaPlot 12 (Systat Software Inc., San Jose, CA).
Normality of the data was tested using the Shapiro-Wilk Normality test after

which statistical analyses were performed using the Kruskal-Wallis ANOVA on
ranks. P-value £ 0.05 was considered statistically significant. (See Appendix for

full analysis.)

5.3

Results

5.3.1 Croton oil induces inflammation at 4 hours after application
Multiple studies have previously used croton oil application as a model of

acute inflammation. However, to validate croton oil-induced ear inflammation as a
successful model of acute inflammation in our hands, paraffin-embedded ear
sections of ears that had been exposed for 4 h exposure to croton oil or to intert

vehicle were stained with an anti-MPO antibody. In absence of croton oil, no
neutrophils were seen in the ear tissue (Figure 5-2a), while in response to the

application of croton oil, numerous MPO positive neutrophils that had extravasated

out of blood vessels and into the tissue were observed (Figure 5-2b). This verifies
that croton oil is a good inducer of neutrophil inflammation, thus making it a nice

model to study leukocyte behavior in acute inflammation.
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Figure 5-2. Croton oil induces neutrophil recruitment after 4 hours of application.
(a) Acetone only treated control ear had no MPO positive cell, while (b) Croton oil application
substantially increases the number of extravasated cells into the ear tissue.

5.3.2 The number of rolling cells induced by chemical injury is lower in TSG6 null ears compared to WT ears.

The number of rolling leukocytes (cells that move slowly along the
endothelial lining for a few seconds, before “popping off”) was determined in WT

control mice, and in TSG-6 null mice to observe the effect that an absence of TSG6 might have upon the rolling behavior of leukocytes. By calculating the rolling cell
numbers per minute normalized by the vessel perimeter, it was observed that
application of croton oil significantly increased the overall rolling behavior in WT
vessels at 4 hours post injury. However, rolling cells in the TSG-6 null vessels were

much less increased by croton oil application. Additionally, a comparison of
leukocyte rolling behavior in WT mice vs TSG-6 null, although not statistically

significant in this pilot experiment, suggested a relative decrease in injury-induced

rolling in TSG-6 null ears relative to WT ears (Figure 5-3, 5-5a -d). Table 5-1 gives
a detailed information on the number of rolling cells counted.
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Figure 5-3. Rolling behavior of leukocytes.
Our analysis suggests that the rolling of leukocytes per minute at 4 hours after application of
croton oil is lower in TSG-6 null mice compared to WT. Statistical analysis was performed
using either the Kruskal-Wallis ANOVA on ranks. (n), number of mice analyzed; NS, Not
significant.

5.3.3 The number of adherent cells induced by chemical injury appears to
be higher in TSG-6 null ears than in WT ears.

Adherent leukocytes (cells that had stopped rolling and become tightly
adherent to the blood vessel wall), were analyzed as described in section 5.2.5, in
both WT mice and in TSG-6 null mice in order to observe any potential differences

in adhesion behavior due to the loss of TSG-6. Calculations of the number of

adherent leukocytes per unit vessel area present at 4 h after application showed
that application of croton oil significantly increases the number of adherent
leukocytes relative to vehicle control, in both WT and TSG-6 null mice. Leukocyte
adhesion is increased more in the TSG-6 null croton oil group, relative to WT group

(Figure 5-4, Table 5-1). While not statistically significant given the small sample

size, this latter difference suggests a very interesting trend.
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Figure 5-4. Adhesion behavior of leukocytes.
Croton oil significantly increases the number of adherent neutrophils in both WT and TSG-6
null groups. The number of these adherent neutrophils in croton oil-treated ears is higher in
TSG-6 null ears than that in WT ears, although the difference is not significant. Statistical
analysis was performed using either the Kruskal-Wallis ANOVA on ranks. (n), number of mice
analyzed; NS= Not significant
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Figure 5-5. Representative images for intravital microscopy of croton oil or acetone
treated ear vessels.
(a) Application of croton oil results in an increase in the population of both rolling and adherent
cells. (b) and (c) Series of images to represent rolling (white arrowhead) vs adherent cells
(blue arrowheads). In green= rhodamine labeled leukocytes; red= vessels labeled with
Qtracker dye; time-stamp, upper right corner; scalebar (50 um), lower right corner.
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Table 5-1. Table detailing the different measurements and calculations for each group
Group

Animal #
WT (1)

WT

WT (2)

Acetone Control

WT (3)

WT (4)

# of leukocytes
# of rolling cells/min # of adherent cells
Vessel Diameter observed in 30 s Vessel Perimeter Vessel surface
(per 10^3 um
(per 10^4 um^2
Rolling Adherent
(um^2)
vessel perimeter)
vessel surface)
(um)
(um)
15.50

5

1

231.0

1550.0

43

6

20.00

0

0

240.0

2000.0

0

0

21.50

0

0

243.0

2150.0

0

0

23.33

0

0

246.7

2333.3

0

0

22.67

0

0

245.3

2266.7

0

0

27.00

0

1

254.0

2700.0

0

4

23.33

3

0

246.7

2333.3

24

0

16.33

0

0

232.7

1633.3

0

0

18.00

0

1

236.0

1800.0

0

6

27.00

9

1

254.0

2700.0

71

4

Average # cells
SEM

WT (1)

WT

WT (2)

Croton Oil
WT (3)
WT (4)

TSG-6 null (2)
TSG-6 null

Acetone Control

TSG-6 null (3)

TSG-6 null (4)

TSG-6 null (1)

TSG-6 null

TSG-6 null (2)

Croton oil
TSG-6 null (3)

TSG-6 null (4)

2

0.83

22.00

11

2

244

2200

90

9

18.50

7

5

237

1850

59

27

19.50

9

4

239

1950

75

21

17.00

8

0

234

1700

68

0

16.00

9

2

232

1600

78

13

53.00

6

3

306

5300

39

6

18.33

1

0

236.67

1833.33

8

0

16.33

2

3

232.67

1633.33

17

18

41.00

0

7

282

4100

0

17

39.00

1

7

278

3900

7

18

Average # cells

44

13

10.73

2.85

SEM

TSG-6 null (1)

14

7.87

26.00

6

0

252

2600

48

0

33.00

4

0

266

3300

30

0

11.50

0

0

223

1150

0

0

21.00

0

0

242

2100

0

0

28.00

0

0

256

2800

0

0

18.67

3

3

237.33

1866.67

25

16

25.33

5

0

250.67

2533.33

40

0

20.67

1

0

241.33

2066.67

8

0

17.67

3

0

235.33

1766.67

25

0

14.00

4

0

228

1400

35

0

25.67

0

0

251.33

2566.67

0

0

Average # cells

19

1

SEM

5.46

1.46

15

0

6

230

1500

0

40

28.33

3

5

256.67

2833.33

23

18

16.00

1

4

232

1600

9

25

44.33

0

0

288.67

4433.33

0

0

13.00

2

1

226

1300

18

8

12

8

1

224

1200

71

8

11.50

2

1

223

1150

18

9

13.67

9

4

227.33

1366.67

79

29
21

14.33

1

3

228.67

1433.33

9

40.33

7

0

280.67

4033.33

50

0

17.00

3

3

234

1700

26

18

Average # cells

28

16

SEM

8.27

3.76

Vessel length= 100 um; Vessel perimeter = 2 * (Vessel length + Vessel diameter);
Vessel surface= Vessel length * Vessel diameter;
SEM= S.D./Ѵ(number of vessel sections quantified)
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5.4

Discussion

This is a preliminary study to determine the effects of loss of TSG-6, a

protein generally known to be anti-inflammatory and a modifier of hyaluronan, in
the rolling and adhesion behavior of leukocytes during inflammation. Using a
model of acute cutaneous inflammation in which a chemical irritant is applied to
the ears of mice and the dynamic behavior of leukocytes (mainly neutrophils in this

model) are observed by intravital confocal microscopy. In a complete experimental

set of 8 mice (4 WT and 4 TSG-6 null mice, each with one ear serving as a bilateral
vehicle-only control), we observed that the number of rolling leukocytes at 4 hours

after application was relatively less in TSG-6 null mice than in WT mice.
Conversely, the number of adherent leukocytes was relatively higher in TSG-6 null
mice than in WT mice. These numbers, although not statistically significant given

the pilot nature of the experiment, are suggestive of possible differences in
leukocyte behavior between the two genotypes and fit with predictions that can be
inferred from the literature (as discussed below).

Previous literature as well as our own findings provide evidence that TSG6 plays an important role in regulating inflammation, by influencing neutrophil

recruitment (Day and Milner 2018). However, the previous lack of any direct
evidence evaluating the effect of TSG-6 upon the individual steps in leukocyte
extravasation motivated us to conduct this study. TSG-6, as discussed in the

chapter Introduction, has mostly been shown to inhibit neutrophil recruitment into
inflamed sites. At the same time, we note that a few studies contradict the notion

that TSG-6 is always anti-inflammatory (Lauer et al. 2013; Swaidani et al. 2013),
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an suggest instead that the effects could be tissue-specific and/or dependent upon
the time point of inflammation observed.

A study by Cao et al. showed that addition of TSG-6 Link module
(Link_TSG-6) in an IL-1b induced peritonitis model causes all three phases of

extravasation (rolling, adhesion and transmigration) to slow down within 2 hours of

IL-1b application. Fewer cells were rolling or adhering in the mesenteric
microcirculation, and fewer cells were recruited into the tissue (Cao et al. 2004).

As the Link_TSG-6 domain consists of the HA binding portion of TSG-6, one can

expect that the observed decrease in neutrophil migration could be accompanied
by modification of HA in the vessel lumen, although this remains to be determined.
Another study investigating the effect of rTSG-6 in an inflammatory air pouch

model showed significant reduction in the number of recruited cells; the authors

postulated that this was due to the ability of TSG-6 to modulate the interaction
between HA and the cell-surface CD44 receptor, thus modulating CD44dependent rolling of leukocytes and ultimately the extravasation of leukocytes
(Wisniewski et al. 1996). Yet another study showed that Link_TSG-6 is sufficient

to inhibit neutrophil migration, independent of its HA or IaI dependent functionality

(Getting et al. 2002). In line with these reports, we observed that in the absence of
TSG-6 in our null mice, the number of adherent leukocytes at 4 h after croton oil

application was higher. This suggests a possibly quicker rolling and stronger

adhesion of leukocytes onto the endothelium in the absence of the inhibitory TSG-

6 molecule, resulting in fewer rolling leukocytes by 4 h of inflammation, while the

number of adherent leukocytes is increased.
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Moreover, TSG-6 has been described to perform anti-inflammatory role by

interrupting the interaction of the glycosaminoglycan (GAG) molecules with various

chemokines. (Chemokines are small protein mediators that are chemotactic for

leukocytes, affecting their activation and migratory behavior). TSG-6 has been
shown to be able to bind to many chemokines as well as to sulfated GAGs such

as chondroitin sulfate, thus competing with the binding of pro-inflammatory

chemokines to GAGs, and to binding of specific chemokines to neutrophils (Dyer
et al. 2016; Dyer et al. 2014). This could also possibly explain the presence of
more adherent neutrophils on the luminal (endothelial) surface in the absence of
TSG-6 in null mice, if in fact they are regulated by cytokines on the GAG-rich

luminal glycocalyx. Since adhesion is the step immediately before transmigration

of leukocytes out of the vessel and into the injury site, a stronger adhesion could
promote more transmigration.

On the other hand, HA is an important part of the glycocalyx of the luminal
side of endothelium (Reitsma et al. 2007). In the study by Swaidani et al., upon

induction of pulmonary inflammation, the bronchoalveolar lavage fluid from TSG-6
null mice contained fewer neutrophils, relative to WT (Swaidani et al. 2013). As
HC-HA complexes are reportedly more leukocyte-adhesive as well as more stable
than HA alone (Day and de la Motte 2005; Lauer et al. 2015b), absence of HC-HA

could lead to a reduction in inflammatory cell invasion into the inflamed lung tissue
in TSG-6 null mice in this study. This could also explain our finding of reduced

neutrophil rolling in TSG-6 null mice, if HA in the glycocalyx cannot be decorated
with HC’s (due to the absence of TSG-6 enzyme) and therefore become less
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sticky. HA has been shown to play roles in leukocyte binding and adhesion to
endothelial surfaces during different inflammatory conditions, such as in diabetes

(Shakya et al. 2015), suggesting that reduced rolling could in fact be due to loss of
HC-HA in the vessel lumen.

In summary, in this Chapter we have presented preliminary findings
suggesting that the absence of TSG-6 affects leukocyte rolling and adhesion. This

question is one that we believe has not been addressed anywhere in the literature

to date. Considering the large number of inflammatory and disease condition in

which TSG-6 has been implicated, we regard these findings as very interesting,
and highly supportive of the need for future experiments. For a more conclusive

result, more animals, ears, and vessels will need to be analyzed, and that is indeed
the future plan for our laboratory.

5.5

Limitations
Following are some limitations of the methodologies involved in this study.

•

The aim of the study was to investigate the difference in neutrophil recruitment
in WT vs TSG-6 null mice. Rhodamine-6G, however, labels all leukocytes in
the blood flow without discrimination. So, the labeled cells we observed could
also be other category of leukocytes and not just neutrophils. An alternative

could be deriving a neutrophil specific GFP labeled TSG-6 null mouse line that
could then be compared with neutrophil specific GFP labeled WT mice.
•

Croton oil ear application is an acute ear inflammation model suitable to study
the early neutrophil recruitment phenotype observed in our TSG-6 null wounds.
But this is inadequate to study the late neutrophil recruitment phenotype
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observed in our earlier study. A possible solution to this could be a full

thickness ear wound model using ear punches to create puncture wounds. The
ear skin around the wounds could then be observed under confocal microscope

at various time points post wounding.
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CHAPTER VI
VI.

6.1

CONCLUSIONS AND RECOMMENDATIONS

Introduction
As

discussed

in

the

earlier chapters,

understanding

the wound

microenvironment is a crucial step towards devising any new treatment
methodology. Earlier studies have investigated tumor necrosis factor-stimulated

gene-6 (TSG-6) in many disease conditions and found that in most situations, it
offers an anti-inflammatory effect. TSG-6 is also known to modify the ubiquitous
extracellular matrix molecule, hyaluronan (HA), by forming complexes between HA

and heavy chains (HC) from the serum; HA and HC-HA have also been shown to
regulate inflammation. In our current work, we found that TSG-6 expression is

increased post-wounding, suggesting that there is much more to understand
regarding how TSG-6 affects the cutaneous wound environment and its probable
therapeutic potential. In this study we sought to explore how loss of endogenous
TSG-6 changes the cutaneous wound environment, including wound closure rates

and the program of inflammation within wounds, by using a mouse model with a

genetic deletion of TSG-6 (TSG-6 null). Experiments in Chapter 3 established that
loss of TSG-6 leads to significant delays in wound closure, and increases the
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expression of pro-inflammatory cytokines in the wounds. Chapters 4 and 5

pioneered methods that will be needed to further investigate the mechanisms of
the abnormal inflammation observed in Chapter 4. Thus, to examine how
macrophage polarization is regulated in TSG-6 null wounds versus wildtype (WT)

wounds, we tested and compile a detailed protocol to isolate single cells
(leukocytes) from wound tissue and perform macrophage population analysis by

flow cytometry. We also developed a method to determine whether loss of TSG-6

affects leukocyte migration behavior in small cutaneous vessels, using intravital

confocal microscopy. The primary research questions pursued in this thesis were:
1. Does loss of TSG-6 affect cutaneous wound closure and inflammation?
2. Can we isolate viable macrophages from skin wounds to investigate

differences in macrophage polarization in TSG-6 null versus WT wounds?

3. Does loss of TSG-6 affect leukocyte rolling and adhesion behavior?

6.2

Findings

The main findings from each chapter are detailed within the text of each
respective chapter. Table 6-1 provides a summary of the outcomes of this work.
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Table 6-1. Summary of the specific aims and the results from the hypotheses explored
in the thesis

Aim

Outcomes
- TSG-6 protein and HC-HA complexes are present in
unwounded murine skin, and increase post wounding.
- There are no redundant enzymes that transfer HC to HA in
the skin
- The absence of TSG-6 results in delayed wound closure.

Aim 1:
Determine how loss
of TSG-6 affects
wound closure and
recruitment of
inflammatory cells

- The absence of TSG-6 results in differential regulation of
neutrophil infiltration into wound bed. While delayed
neutrophil recruitment was observed in early wounds,
exacerbated inflammation was observed in later wounds
- TSG-6 null mice develop an abnormal pro-inflammatory
wound environment.
- Absence of TSG-6 does not affect macrophage recruitment
but affects the polarization of macrophages. Wound
macrophages are polarized towards the pro-inflammatory
M1 phenotype TSG-6 null mice.
- Reintroduction of recombinant TSG-6 into TSG-6 null
wounds rescues the delayed wound closure and differential
neutrophil recruitment.

Aim 2:

Develop a viable
protocol to isolate
single cells from
cutaneous wounds
for flow sorting and
flow cytometric
assessment of
leukocytes in WT
and TSG-6 null
wounds, with a
particular emphasis
on macrophages

- Validated the isolation of viable single cells from cutaneous
wounds.
- After antibody staining of the isolated viable single cells, the
macrophage-specific population was successfully sorted for
RNA analysis.
- Isolated viable single cells were successfully stained for
M1/M2 phenotype specific markers and flow cytometric
analysis was performed.
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Aim 3:
Determine how the
absence of TSG-6
affects rolling and
adhesion behavior
of leukocytes in vivo
after chemical injury
using intravital
microscopy

6.3

- Croton oil application was shown to be an efficient model of
inflammation, by inducing the recruitment of leukocytes at
sites of chemical injury.
- Preliminary findings showed that the number of rolling cells
(leukocytes) induced by chemical injury is lower in TSG-6 null
ears than in WT ears.
- The number of adherent cells induced by chemical injury
appears to be higher in TSG-6 null ears than in WT ears.

Recommendation for future research

There were a number of limitations of this study, and some research ideas
beyond the scope of this study. What follows are recommendations for some future
experiments to extend and apply the results of this thesis work.

1. It is known that HA is a present in the endothelial glycocalyx of small blood
vessels and plays a role in regulating adhesion of leukocytes to the

endothelium in different inflammatory conditions such as atherosclerosis and

diabetes. TSG-6 modifies HA forming HC-HA which is also upregulated in skin

wounds along with TSG-6 and there is no compensatory molecule for this
enzymatic action in TSG-6 null wounds. Therefore, it will be interesting to
investigate whether the HA in the glycocalyx is complexed to HC under normal

wounding conditions, and whether HC-HA regulates leukocyte rolling and/or
adhesion during inflammation.
2. Angiogenesis is an important factor in normal wound healing. This aspect has
not been directly investigated in this study, but is highly recommended as a

topic of future investigation.
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3. An important aspect of wound healing, beyond the scope of this study, is
fibroblast proliferation and fibrosis. The extent of fibrosis (scarring) is well
known to be dependent upon inflammation in the wound. Therefore, It will be
informative to evaluate the later stages of wound healing in the TSG-6 null mice

to see whether there are any differences in the tissue formation phase or the
tissue reparative phase.

4. Immunohistological staining of the Day 7 wound sections suggested

differences (increases) in the M1/M2 ratio in TSG-6 null vs WT wounds
(Chapter 3). In our study we only explored Day 7 wounds for this purpose.
However, M1/M2 is not a discrete phenomenon but rather a continuous one.
Thus, in the future, it will be important to determine how macrophage

polarization progresses at different time point post-wounding. Adding more
markers, in addition to CD38 (M1) and Arginase-1 (M2), will be helpful in this

regard.

5. Flow cytometric analysis is known to be a reliable technique to characterize
single cells within cell populations. Chapter 4 of this thesis developed a detailed
protocol to isolate viable, single leukocytes from wounds. Future studies, using
thses flow cytometric procedures, could be very helpful in determining the

expression levels of M1/M2 specific marker proteins at different time points
after wounding,

thereby

revealing

possible

changes

in

macrophage

polarization related to the absence of TSG-6.

In this thesis, we performed a preliminary investigation of the rolling and
adhesion steps during leukocyte extravasation in TSG-6 null and WT mice. A
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recommended next step is to observe the transmigration step, which following

adhesion, directly. Although differences in rolling and/or adhesion behaviors may
be indicative of differential recruitment of leukocytes, having additional information

about transmigration through the endothelium would be helpful in explaining
neutrophil recruitment phenotypes observed in the wounding experiments.

6.4

Conclusion
This thesis work highlighted the role of TSG-6 in the regulation of wound

healing, with a special focus on inflammation. One of the strongest aspects of the
study is the confirmation of a rescue effect observed after addition of recombinant

TSG-6; this experiment verified that the phenotypes we observe in TSG-6 null
wounds are specifically due to loss of TSG-6. Another important contribution of this
study is the creation of a detailed methodology to isolate single, viable leukocytes

from the wound bed and to process them for staining and/or RNA analysis. We

believe that the details of this procedure, which have rarely been previously
attempted, will be helpful in future investigations.
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APPENDIX

Figure 3-1b:
Monday, September 23, 2019, 11:41:54 Pi

One Way Repeated Measures Analysis of Variance

Data source: Data 1 in TSG6protein_WT ExW 02-14-18
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Treatment Name
uW
12 h
Dayl
Day 3
Day5
Day 7
Day 10

N
5
5
4
5
4
5
5

Source of Variation
Between Subjects
Between Treatments
Residual
Total

Failed (P < 0.050)

Passed (P = 0.364)

Missin<g
0
0
0
0
0
0
0
DF
4
6
22
32

Std Dev
0.217
1.569
1.312
3.171
1.127
0.593
1.558

Mean
1.000
4.497
4.568
5.136
3.188
2.178
2.519

SS
15.045
63.930
55.290
136.592

MS
3.761
10.655
2.513
4.269

SEM
0.0971
0.701
0.656
1.418
0.564
0.265
0.697

F

P

4.240

0.006

The differences in the mean values among the treatment groups are greater than would be expected by
chance; there is a statistically significant difference (P = 0.006). To isolate the group or groups that differ
from the others use a multiple comparison procedure.

Power of performed test with alpha = 0.050: 0.839
Expected Mean Squares:
Approximate DF Residual = 22.000
Expected MS(Subj) = var(res) + 6.500 var(Subj)
Expected MS(Treatment) = var(res) + var(Treatment)
Expected MS (Residual) = var(res)
Multiple Comparisons versus Control Group (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison

uW vs. Day 3
uW vs. 12 h
uW vs. Dayl
uW vs. Day5
uW vs. Day 10
uW vs. Day 7

Diff of Means

t

P

P<0.050

4.136
3.497
3.296
1.916
1.519
1.178

4.125
3.488
3.066
1.782
1.515
1.175

0.003
0.010
0.022
0.243
0.267
0.253

Yes
Yes
Yes
No
No
No
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Figure 3-1b:
Monday. September 23, 2019, 11:49:07 PM

t-test

Data source: Data 1 in Figure 3-ld_HC-HA assay
Normality Test (Shapiro-Wilk)

Passed (P = 0.516)

Equal Variance Test:

Passed (P = 0.435)

Group Name
N
Fold change uW
3
Fold change ExW 3

Missing
0
0

Difference

Mean
1.000
2.697

Std Dev
0.300
0.0899

SEM
0 173
0.0519

-1.697

t = -9.376 with 4 degrees of freedom. (P = <0.001)
95 percent confidence interval for difference of means: -2.199 to -1.194

The difference in the mean values of the two groups is greater than would be expected by chance; there is a
statistically significant difference between the input groups (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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Figure 3-3:
Day 3 Excisional wound

Monday, September 23, 2019, 11:54:02 PM

t-test

Data source: Data 1 in Figure 3-3_Wound closure WTvsTSGónull
Normality Test (Shapiro-Wilk)

Failed (P < 0.050)

Test execution ended by user request. Rank Sum Test begun

Mann-Whitney Rank Sum Test

Monday, September 23, 2019, 11:54:02 PM

Data source: Data 1 m Figure 3-3_Wound closure WTvsTSGónull

Group
WT Day 3
TSG-6 null Day 3

N
20
20

Missing
0
0

25%
49646
60.104

Median
60.724
68.654

75%
66.180
90.453

Mann-WTutney U Statistic= 124.000
T = 334.000 n(small)= 20 n(big)=20 (P = 0 041)

The difference in the median values between the two groups is greater than would be expected by chance:
there is a statistically significant difference (P = 0.041)

Day 5 Excisional wound

Monday. September 23, 2019, 11:54:17 PM

t-test

Data source: Data 1 in Figure 3-3_Wound closure WTvsTSG6null
Normality Test (Shapiro-Wilk)

Failed (P < 0.050)

Test execution ended by user request. Rank Sum Test begun
Mann-Whitney Rank Sum Test

Monday, September 23, 2019, 11:54:17 PM

Data source: Data 1 in Figure 3-3_Wound closure WTvsTS6ónull
Group
WT Day 5
TSG-6 null Day 5

N
20
20

Missing
0
0

Median
50.116
67.621

25%
41.706
45.614

75%
57.361
90.832

Mann-Whitney U Statistic= 121.000
T = 331.000 n(small)= 20 n(big)=20 (P = 0.034)

The difference in the median values between the two groups is greater than would be expected by chance:
there is a statistically significant difference (P = 0.034)
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Day 7 Excisional wound

Monday. September 23, 2019, 11:54:37 PM

t-test

Data source: Data 1 in Figure 3-3_Wound closure WTvsTSG6null

Normality Test (Shapiro-Wilk)

Passed (P = 0.275)

Equal Variance Test:
Group Name
WT Day 7
TSG-6 null Day 7
Difference

Passed (P = 0.333)

N
20
20

Missing
0
0

Mean
32.445
50.693

Std Dev
17.590
27.283

SEM
3.933
6.101

-18.247

t = -2.514 with 38 degrees of freedom. (P = 0.016)
95 percent confidence interval for difference of means: -32.941 to -3.553

The difference in the mean values of the two groups is greater than would be expected by chance; there is a
statistically significant difference between the input groups (P = 0.016).
Power of performed test with alpha = 0.050: 0.612

Day 10 Excisional wound

Monday, September 23, 2019, 11:54:58 PM

t-test

Data source: Data 1 in Figure 3-3_Wound closure WTvsTSG6null

Normality Test (Shapiro-Wilk)

Passed (P = 0.568)

Equal Variance Test:

Group Name
WT Day 10
TSG-6 null Day 10
Difference

Passed (P = 0.426)

N
10
10

Missing
0
0

Mean
13.092
19.310

Std Dev
4.855
5.352

SEM
1.535
1.692

-6.218

t = -2.721 with 18 degrees of freedom (P = 0.014)
95 percent confidence interval for difference of means: -11.018 to -1.417

The difference in the mean values of the two groups is greater than would be expected by chance; there is a
statistically significant difference between the input groups (P = 0.014).
Power of performed test with alpha = 0.050: 0.671
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Figure 3-4:
Day 1 Excisional wound

Tuesday, September 24, 2019, 12:23:34 AM

t-test

Data source: Data 1 in Figure 3-4_Re-epithelialization
Normality Test (Shapiro-Wilk)

Failed (P < 0.050)

Test execution ended by user request. Rank Sum Test begun
Mann-Whitney Rank Sum Test

Tuesday. September 24, 2019, 12:23:34 AM

Data source: Data 1 in Figure 3-4_Re-epithelialization

Group
Day 1 WT
Day 1 TSG-6 null

N
4
4

Missing
0
0

Median
0.000
0.000

75%
1.369
0.648

25%
0.000
0.000

Mann-Whitney U Statistic= 7.500

T = 18.500 n(small)= 4 n(big)= 4 P(est.)= 1.000 P(exact)= 0.886

The difference in the median values between the two groups is not great enough to exclude the possibility
that the difference is due to random sampling variability: there is not a statistically significant difference (P
= 0.886)
Day 3 Excisional wound

Tuesday. September 24. 2019. 12:23:46 AM

t-test
Data source: Data 1 in Figure 3-4_Re-epithelialization

Normality Test (Shapiro-Wilk)

Failed (P < 0.050)

Test execution ended by user request. Rank Stun Test begun
Tuesday. September 24. 2019. 12:23:46 AM

Mann-Whitney Rank Sum Test
Data source: Data 1 in Figure 3-4_Re-epithelialization

Group
Day 3 WT
Day 3 TSG-6 null

N
7
8

Missing
0
0

Median
11.569
13.557

25%
6.686
8.798

75%
15.399
29.748

Mann-Whitney U Statistic= 21.000

T = 49.000 n(small)= 7 n(big> 8 P(est.)= 0.452 P(exact)= 0.463

The difference in the median values between the two groups is not great enough to exclude the possibility
that the difference is due to random sampling variability: there is not a statistically significant difference (P
= 0.463)
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Day 5 Excisional wound

t-test

Tuesday, September 24, 2019,12:23:55 AM

Data source: Data 1 in Figure 3-4_Re-epithelialization

Normality Test (Shapiro-Wilk)

Equal Variance Test:

Difference

Passed (P = 0.341)

N
8
7

Group Name
Day 5 WT
Day 5 TSG-6 null

Passed (P = 0.288)

Missing
0
0

Mean
84.379
54.366

Std Dev
22.447
28.348

SEM
7.936
10.714

30.013

t = 2.288 with 13 degrees of freedom (P = 0.040)
95 percent confidence interval for difference of means: 1.679 to 58.348

The difference in the mean values of the two groups is greater than would be expected by chance; there is a
statistically significant difference between the input groups (P = 0.040).

Power of performed test with alpha = 0.050: 0.470

Day 7 Excisional wound

Tuesday. September 24, 2019, 12:24:05 AM

t-test

Data source: Data 1 in Figure 3-4_Re-epithelialization
Normality Test (Shapiro-Wilk)

Failed (P < 0.050)

Test execution ended by user request. Rank Stun Test begun

Mann-Whitney Rank Sum Test

Tuesday. September 24, 2019, 12:24:05 AM

Data source: Data 1 in Figure 3-4_Re-epithelialization
Group
Day 7 WT
Day 7 TSG-6 null

N
10
9

Missing
0
0

Median
100.000
60.899

25%
99.000
25.225

75%
100.000
100.000

Mann-Whitney U Statistic= 19.500
T = 64.500 n(small)= 9 n(big)= 10 (P = 0.027)

The difference in the median values between the two groups is greater than would be expected by chance;
there is a statistically significant difference (P = 0.027)
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Day 10 Excisional wound

Tuesday. September 24, 2019. 12:24:15 AM

t-test

Data source: Data 1 in Figure 3-4_Re-epithelialization

Failed

Normality Test (Shapiro-Wilk)

(P < 0.050)

Test execution ended by user request. Rank Stun Test begun
Tuesday. September 24. 2019. 12:24:15 AM

Mann-Whitney Rank Sum Test

Data source: Data 1 in Figure 3-4_Re-epithelialization
Group

Day 10 WT
Day 10 TSG-6 null

N

9
10

Missing

0
0

Median

100.000
100.000

25%

75%

94.997
86.348

100.000
100.000

Mann-Whitney U Statistic= 39.500

T = 95.500 n(smaU)= 9 n(big)= 10 (P = 0.637)

The difference in the median values between the two groups is not great enough to exclude the possibility
that the difference is due to random sampling variability; there is not a statistically significant difference (P
= 0.637)
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Figure 3-5:
12h Excisional wound

Tuesday, September 24, 2019, 12:38:08 AM

t-test

Data source: Data 1 in Figure 3-5_Neutrophil Quantification_Breadloaf Method

Normality Test (Shapiro-Wilk)

Passed (P = 0.560)

Equal Variance Test:

(P < 0.050)

Failed

Test execution ended by user request. Rank Sum Test begun
Tuesday, September 24, 2019, 12:38:08 AM

Mann-Whitney Rank Sum Test

Data source: Data 1 in Figure 3-5_Neutrophil Quantification_Breadloaf Method

Group
12hWT
12h TSG6 null

N
23
20

Median
114.898
51 683

Missing
0
0

25%
40.542
23.962

75%
165.081
80.310

Mann-Whitney U Statistic= 122.000
T = 332.000 n(small)= 20 n(big)= 23 (P = 0.009)

The difference in the median values between the two groups is greater than would be expected by chance:
there is a statistically significant difference (P = 0.009)

Day 1 Excisional wound

Tuesday. September 24, 2019, 12:38:18 AM

t-test

Data source: Data 1 in Figure 3-5_Neutrophil Quantification_Breadloaf Method

Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request. Rank Stun Test begun
Tuesday. September 24, 2019. 12:38:18 AM

Mann-Whitney Rank Sum Test

Data source: Data 1 in Figure 3-5_Neutrophil Quantification_Breadloaf Method

Group
Dayl WT
Day 1 TSG-6 null

N
21
21

Missing
0
0

Median
75.336
51.256

25%
44.233
31.772

75%
122.118
84.220

Mann-Whitney U Statistic= 153.000
T = 519.000 n(small)=21 n(big)= 21 (P = 0.092)

The difference in the median values between the two groups is not great enough to exclude the possibility
that the difference is due to random sampling variability: there is not a statistically significant difference (P
= 0.092)
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Day 3 Excisional wound

Tuesday, September 24, 2019, 12:38:32 AM

t-test

Data source: Data 1 in Figure 3-5_Neutrophil QuantificationBreadloaf Method

Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request. Rank Sum Test begun
Tuesday, September 24, 2019, 12:38:32 AM

Mann-Whitney Rank Sum Test

Data source: Data 1 in Figure 3-5_Neutrophil Quautification Breadloaf Method
Group

Day3 WT
Day3 TSG-6 null

N

17
17

Missing

Median

25%

75%

0
0

80.016
71.019

64.860
36.827

101.183
110.587

Mann-Whitney U Statistic= 140.000

T = 302.000 n(small)= 17 n(big)= 17 (P = 0.890)

The difference in the median values between the two groups is not great enough to exclude the possibility
that the difference is due to random sampling variability; there is not a statistically significant difference (P
= 0.890)

Day 5 Excisional wound

Tuesday, September 24, 2019. 12:38:41 AM

t-test

Data source: Data 1 in Figure 3-5_Neutrophil QuantificationBreadloaf Method
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request. Rank Sinn Test begun
Tuesday, September 24, 2019. 12:38:41 AM

Mann-Whitney Rauk Sum Test

Data source: Data 1 in Figure 3-5_Neutroplhil Quantification Breadloaf Method
Group

Day5 WT
Day5 TSG-6 null

N

10
13

Missing

Median

25%

75%

0
0

46.478
43.679

24.450
27.456

105.458
109.829

Mann-Whitney U Statistic= 61.000

T = 124.000 n(small)= 10 n(big)= 13 (P = 0.828)
The difference in the median values between the two groups is not great enough to exclude the possibility
that the difference is due to random sampling variability; there is not a statistically significant difference (P
= 0.828)
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Day 7 Excisional wound

Tuesday, September 24, 2019, 12:39:02 AM

t-test

Data source: Data 1 in Figure 3-5_Neutrophil QuantificationBreadloaf Method

(P < 0.050)

Failed

Normality Test (Shapiro-Wilk)

Test execution ended by user request, Rank Sum Test begun
Tuesday, September 24, 2019, 12:39:02 AM

Mann-Whitney Rank Sum Test

Data source: Data 1 in Figure 3-5_Neutrophil Quantification Breadloaf Method

Group

N

Missing

Day7 WT
Day7 TSG-6 null

17
18

0
0

Median

63.332
151.543

25%

75%

43.748
120.124

108.457
237.908

Mann-Whitney U Statistic= 35.000

T = 188.000 n(small)= 17 n(big)= 18 (P = <0.001)

The difference in the median values between the two groups is greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)

Day 10 Excisional wound

Tuesday, September 24, 2019, 12:39:14 AM

t-test

Data source: Data 1 in Figure 3-5_Neutrophil Quantification Breadloaf Method

Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begtm
Tuesday, September 24, 2019, 12:39:14 AM

Mann-Whitney Rank Sum Test

Data source: Data 1 in Figure 3-5_Neutrophil Quantification Breadloaf Method

Group

Day 10 WT
Day 10 TSG-6 null

N

15
14

Missing

Median

0
0

11.979
11.006

25%

6.028
7.155

75%

39.603
20.926

Mann-Whitney U Statistic= 93.000
T = 198.000 n(small)= 14 n(big)= 15 (P = 0.616)
The difference in the median values between the two groups is not great enough to exclude the possibility
that the difference is due to random sampling variability; there is not a statistically significant difference (P
= 0.616)
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Figure 3-6:
No wound

Tuesday, September 24, 2019, 12:50:07 AM

t-test

Data source: Data 1 in Figure 3-6_TNFa WTvsTSG-6null ExW
Normality Test (Shapiro-Wilk)

Passed (P = 0.340)

Equal Variance Test:

Group Name

N

Missing

Mean

Std Dev

SEM

0
0

0.542
1.010

0.348
0.562

0.156
0.251

NoWound WT 5
NoWound TSG-6 5
Difference

Passed (P = 0.879)

-0.469

t = -1.585 with 8 degrees of freedom. (P = 0.152)

95 percent confidence interval for difference of means: -1.150 to 0.213

The difference in the mean values of the two groups is not gr eat enough to reject the possibility that the
difference is due to random sampling variability. There is not a statistically significant difference between
the input groups (P = 0.152).
Power of performed test with alpha = 0.050: 0.184

The power of the performed test (0.184) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists.
Negative results should be interpreted cautiously.
12h Excisional wound

Tuesday, September 24, 2019, 12:50:14 AM

t-test

Data source: Data 1 in Figure 3-6 TNFa WTvsTSG-6null ExW
Normality Test (Shapiro-Wilk)

Equal Variance Test:

Passed (P = 0.602)

Passed (P = 0.258)

Group Name

N

Missing

Mean

Std Dev

SEM

12h WT
12h TSG-6 null

5
5

0
0

0.566
1.597

0.251
0.391

0.112
0.175

Difference

-1.031

t = -4.959 with 8 degr ees of freedom. (P = 0.001)

95 percent confidence interval for difference of means: -1.511 to -0.552

The difference in the mean values of the two groups is greater than would be expected by chance; there is a
statistically significant difference between the input groups (P = 0.001).
Power of performed test with alpha = 0.050: 0.992
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Day 3 Excisional wound

Tuesday, September 24, 2019, 12:50:22 AM

t-test

Data source: Data 1 in Figure 3-6_ TNFa WTvsTSG-6null ExW
Normality Test (Shapiro-Wilk)

Passed (P = 0.668)

Equal Variance Test:

Passed (P = 0.807)

Group Name
Day3 WT
Day3 TSG-6 null

Missing
0
0

Difference

N
5
5

Mean
0.780
1.043

Std Dev
0.305
0.263

SEM
0.136
0.118

-0.263

t = -1.460 with 8 degrees of freedom. (P = 0 .182)

95 percent confidence interval for difference of means: -0.678 to 0.152
The difference in the mean values of the two groups is not great enough to reject the possibility that the
difference is due to random sampling variability. There is not a statistically significant difference between
the input groups (P = 0.182).

Power of performed test with alpha = 0.050: 0.149
The power of the performed test (0.149) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists.
Negative results should be interpreted cautiously.

Day 5 Excisional wound

Tuesday, September 24, 2019, 12:50:32 AM

t-test

Data source: Data 1 in Figure 3-6_TNFa WTvsTSG-6null ExW

Normality Test (Shapiro-Wilk)

Passed (P = 0.402)

Equal Variance Test:

Passed (P = 0.239)

Group Name
Day5 WT
Day5 TSG-6 null

Missing
0
0

Difference

N
4
4

Mean
0.651
0.941

Std Dev
0.115
0.416

SEM
0.0577
0.208

-0.290

t = -1.344 with 6 degrees of freedom. (P = 0.228)

95 percent confidence interval for difference of means: -0.819 to 0.238
The difference in the mean values of the two groups is not great enough to reject the possibility that the
difference is due to random sampling variability. There is not a statistically significant difference between
the input groups (P = 0.228).

Power of performed test with alpha = 0.050: 0.114
The power of the performed test (0.114) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists.
Negative results should be interpreted cautiously.

160

Day 7 Excisional wound

t-test

Tuesday, September 24. 2019, 12:50:40 AM

Data source: Data 1 in Figure 3-6_TNFa WTvsTSG-6null ExW
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.833)

Passed (P = 0.609)

Group Name

N

Missing

Mean

Std Dev

SEM

Day7 WT
Day7 TSG-6 null

5
4

0
0

0.432
2.457

0.443
0.850

0.198
0.425

Difference

-2.026

t = -4.647 with 7 degrees of freedom. (P = 0.002)

95 percent confidence interval for difference of means: -3.056 to -0.995

The difference in the mean values of the two groups is greater than would be expected by chance; there is a
statistically significant difference between the input groups (P = 0.002).
Power of performed test with alpha = 0.050: 0.977
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Figure 3-7:
Day 5 Excisional wound

Tuesday, September 24, 2019, 12:54:41 AM

t-test

Data source: Data 1 in Figure 3-7 Macrophage QuantificationBreadloaf Method
Normality Test (Shapiro-Wilk)

Failed (P < 0.050)

Test execution ended by user request. Rank Sum Test begun
Tuesday, September 24, 2019, 12:54:41 AM

Mann-Whitney Rank Sum Test

Data source: Data 1 in Figure 3-7 Macrophage Quantification Breadloaf Method
Group
Day5 WT
Day5 TSG-6 null

N
16
15

Median
33.555
30.419

Missing
0
0

25%
16.488
18.818

75%
62.779
49.811

Mann-Whitney U Statistic= 113.000

T = 233.000 n(small)= 15 n(big)= 16 (P = 0.797)
The difference in the median values between the two groups is not great enough to exclude the possibility
that the difference is due to random sampling variability; there is not a statistically significant difference (P
= 0.797)
Day 7 Excisional wound

Tuesday. September 24, 2019, 12:54:48 AM

t-test

Data source: Data 1 in Figure 3-7_Macrophage Quantification Breadloaf Method

Normality Test (Shapiro-Wilk)

Passed (P = 0.331)

Equal Variance Test:

Passed (P = 0.184)

Group Name
Day7 WT
Day7 TSG-6 null

Missing
0
0

Difference

N

13
21

Mean
73.701
57.190

Std Dev
36.368
27.341

SEM
10.087
5.966

16.512

t = 1.508 with 32 degrees of freedom. (P = 0.141)

95 percent confidence interval for difference of means: -5.798 to 38.821
The difference in the mean values of the two groups is not great enough to reject the possibility that the
difference is due to random sampling variability. There is not a statistically significant difference between
the input groups (P = 0.141).

Power of performed test with alpha = 0.050: 0.182
The power of the performed test (0.182) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists.
Negative results should be interpreted cautiously.

162

Figure 3-8a:
Tuesday, September 24, 2019, 1:00:38 AM

t-test

Data source: Data 1 in Figure 3-8a_CD38 staining
Normality Test (Shapiro-Wilk)

Passed (P = 0.931)

Equal Variance Test:

Passed (P = 0.546)

Group Name

N

Missing

Mean

Std Dev

SEM

CD38/F480 WT
CD38/F480 TSG-6null

7
7

0
0

0.197
0.594

0.116
0.157

0.0440
0.0593

Difference

-0.397

t = -5.380 with 12 degrees of freedom. (P = <0.001)

95 percent confidence interval for difference of means: -0.558 to -0.236

The difference in the mean values of the two groups is gr eater than would be expected by chance; there is a
statistically significant difference between the input groups (P = <0.001).
Power of performed test with alpha = 0.050: 0.999
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Figure 3-8b:
Tuesday, September 24, 2019, 1:05:06 AM

t-test
Data source: Data 1 in Figure 3-8b_Arginase-l staining

Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Tuesday, September 24, 2019, 1:05:06 AM

Mann-Whitney Rank Sum Test

Data source: Data 1 in Figure 3-8b_Arginase-l staining
Group

N

Arg-l/F480_WT
Arg-l/F480_TSG-6 null

20
21

Missing

0
0

Median

0.496
0.209

25%

0.266
0.0922

75%

0.713
0.511

Mann-Whitney U Statistic= 116.000
T = 514.000 n(small)= 20 n(big)=21 (P = 0.015)

The difference in the median values between the two groups is greater than would be expected by chance;
there is a statistically significant difference (P = 0.015)
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Figure 3-9c:
Two Way Analysis of Variance

Tuesday, September 24, 2019, 3:57:35 AM

Data source: rTSG-6 Wound Closure in Figure 3-9_Wound closure rTSG-6 Experiment
Balanced Design

Dependent Vanable: Wound Area

Normality Test (Shapiro-Wilk)

Passed (P = 0.212)

Equal Variance Test:

Passed (P = 0.582)

Source of Variation
Genotype
Treatment
Genotype x Treatment
Residual
Total

DF
1
1
1
28
31

MS
90.473
58.801
2825.805
194.493
271 642

SS
90.473
58.801
2825.805
5445.818
8420896

F

0.465
0.302
14.529

P
0.501
0.587
<0.001

Mam effects cannot be properly interpreted if significant interaction is determmed. This is because the size
of a factor's effect depends upon the level of the other factor.

The effect of different levels of Genotype depends on what level of Treatment is present. There is a
statistically significant interaction between Genotype and Treatment. (P = <0.001)
Power of performed test with alpha = 0.0500: for Genotype : 0.0500
Power of performed test with alpha = 0.0500: for Treatment: 0.0500
Pow'er of performed test with alpha = 0.0500: for Genotype x Treatment: 0.958
Least square means for Genotype :
Group
Mean
WT
42.085
TSG-6 null 38.722
Std Err of LS Mean = 3.487
Least square means for Treatment:
Group
Mean
Vehicle Control
39.048
rTSG-6
41.759
Std Err of LS Mean = 3.487
Least square means for Genotype x Treatment:
Group
Mean
WT x Vehicle Control
31.332
WT x rTSG-6
52.838
TSG-6 null x Vehicle Control
46.764
TSG-6 null x rTSG-6
30.681
Std Err of LS Mean = 4.931

All Pairwise Multiple Comparison Procedures (Bonferroni t-test):
Comparisons for factor: Genotype
Comparison
Diff of Means

t

P
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P<0.050

WT vs. TSG-6 null

3.363

0.501

0.682

No

Comparisons for factor: Treatment
Comparison
Diff of Means
rTSG-6 vs. Vehicle Control
2.711

t
0.550

P
0.587

P<0.050
No

Comparisons for factor: Treatment within WT
Comparison
Diff of Means
rTSG-6 vs. Vehicle Control
21.505

t
3.084

P
0.005

P<0.05
Yes

Comparisons for factor: Treatment within TSG-6 null
Comparison
Diff of Means
t
Vehicle Control vs. rTSG-6
16.083
2.306

P
0.029

P<0.05
Yes

Comparisons for factor: Genotype within Vehicle Control
Comparison
Diff of Means
t
TSG-6 null vs. WT
15.431
2.213

P
0.035

P<0.05
Yes

Comparisons for factor: Genotype within rTSG-6
Comparison
Diff of Means
WT vs. TSG-6 null
22.157

P
0.004

P<0.05
Yes

166

t
3 178

Figure 3-9d:
Two Way Analysis of Variance

Tuesday, September 24, 2019, 4:01:12 AM

Data source: NeutRecruitment_12hours in Figure 3-9d_Neutrophil Quant_Breadloaf_rTSG-6 Experiment

General Linear Model
Dependent Variable: Neutrophils

Normality Test (Shapiro-Wilk)

Passed (P = 0.110)

Equal Variance Test:

Passed (P = 0.060)

Source of Variation
Genotype
Treatment
Genotype x Treatment
Residual
Total

DE
1
1
1
100
103

SS
6928.113
8.858
4427.035
49396.971
60380.444

MS
6928.113
8.858
4427.035
493.970
586.218

F
14.025
0.0179
8962

P
<0.001
0.894
0.003

Mam effects cannot be properly interpreted if significant interaction is determined. This is because the size
of a factor's effect depends upon the level of the other factor.

The effect of different levels of Genotype depends on what level of Treatment is present. There is a
statistically significant interaction between Genotype and Treatment. (P = 0.003)
Power of performed test with alpha = 0.0500: for Genotype : 0.963
Power of performed test with alpha = 0.0500: for Treatment : 0.0500
Power of performed test with alpha = 0.0500: for Genotype x Treatment: 0.813
Least square means for Genotype :
Group
Mean
SEM
WT
46.874
3.119
TSG-6 null 30.427
3.091
Least square means for Treatment:
Group
Mean
SEM
Vehicle Control
38.945
3.166
rTSG-6
38.357
3.043
Least square means for Genotype x Treatment :
Group
Mean
53.741
WT x Vehicle Control
WT x rTSG-6
40.006
TSG-6 null x Vehicle Control
24.148
TSG-6 null x rTSG-6
36.707

SEM
4.738
4.058
4.200
4.537

All Pairwise Multiple Comparison Procedures (Bonferroni t-test):

Comparisons for factor: Genotype
Comparison
Diff of Means

t

P
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P<0.050

3.745

<0.001

Yes

Comparisons for factor: Treatment
Comparison
Diff of Means
Vehicle Control vs. rTSG-6
0.588

t
0.134

P
0.894

Comparisons for factor: Treatment within MT
Comparison
Diff of Means
Vehicle Control vs. rTSG-6
13.735

t
2.202

P
0.030

P<0.05
Yes

Comparisons for factor: Treatment within TSG-6 null
Comparison
Diff of Means
t
rTSG-6 vs. Vehicle Control
12.559
2.031

P
0.045

P<0.05
Yes

Comparisons for factor: Genotype within Vehicle Control
Comparison
Diff of Means
t
WT vs. TSG-6 nuB
29.593
4 674

P
<0.001

P<0.05
Yes

P
0.589

P<0.05
No

WT vs. TSG-6 nuD

16 447

Comparisons for factor: Genotype within rTSG-6
Comparison
Diff of Means
WT vs. TSG-6 nuU
3.300

t
0.542

168

P<0.050
No

Figure 3-9e:
Tuesday. September 24. 2019. 4:45:34 AM

Kruskal-Wallis Oue Way Analysis of Variance ou Rauks

Data source: NeutRecruitment_Day7 in Figure 3-9e_Day7 Neutrophil Quant_Breadloaf_rTSG-6

Experiment
Normality Test (Shapiro Wilk)

Group

N

WT Vehicle Control
WT +rTSG-6
TSG-6 Vehicle Control
TSG-6 null +rTSG-6

24
18
23
17

Failed (P < 0.050)
Missing
0
0
0
0

Median

25%

2.842
2.759
9.466
2.367

1.554
1.975
3.795
1.277

75%

6.603
4.355
19.826
4.766

H = 21.518 with3 degrees of freedom. (P = <0.001)

The differences in the median values among the treatment groups are greater than would be expected by
chance; there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.

All Pairwise Multiple Comparison Procedures (Drum's Method)
Comparison

TSG-6 Vehicle vs TSG-6 null +r
TSG-6 Vehicle vs WT +rTSG-6
TSG-6 Vehicle vs WT Vehicle Co
WT Vehicle Co vs TSG-6 null +r
WT Vehicle Co vs WT +rTSG-6
WT +rTSG-6 vs TSG-6 null +r

Diff of Rauks

31.256
25.053
24.359
6.897
0.694
6.203

Q
4.103
3.343
3.505
0.914
0.0935
0.770

P<0.05

Yes
Yes
Yes
No
Do Not Test
Do Not Test

Note: The multiple comparisons on ranks do not include an adjustment for ties.
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Figure 4-7:
Tuesday, September 24, 2019, 4:38:57 AM

t-test

Data source: Data 1 in Figure 4-7_Adgrel_rtPCR_FACS sorted Macrophages
Normality Test (Shapiro-Wilk)

Equal Variance Test:

Passed (P = 0.584)

Passed (P = 0.053)

Group Name

N

Missing

Mean

Std Dev

SEM

dCt CD45 only
dCt CD45+F4/80+ Macrophages

5
6

0
0

19.794
13.541

1.418
0.422

0.634
0.172

Difference

6.253

t = 10.365 with 9 degrees of freedom. (P = <0.001)
95 percent confidence interval for difference of means: 4.888 to 7.618

The difference in the mean values of the two groups is greater than would be expected by chance; there is a
statistically significant difference between the input groups (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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Figure 5-3:
Kruskal-Wallis One Way Analysis of Variance on Ranks

Tuesday, September 24, 2019, 5:01:00 AM

Data source: Data 1 in Figure 5-3_Leukocyte rolling behavior WT vs TSG6 null

Normality Test (Shapiro-Wilk)

Group

WT Acetone Control
WT Croton Oil
TSG-6 null Acetone Control
TSG-6 null Croton Oil

Failed
N

10
10
11
11

(P < 0.050)

Missing

Median

0
0
0
0

0.000
49.144
25.281
17.937

25%

0.000
8.137
0.000
8.621

75%

29.066
75.882
35.088
49.881

H = 6.888 with 3 degrees of freedom. (P = 0.076)
The differences in the median values among the treatment groups are not great enough to exclude the
possibility that the difference is due to random sampling variability; there is not a statistically significant
difference (P = 0.076)
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Figure 5-4:
Kruskal-Wallis One Way Analysis of Variance on Ranks

Tuesday, September 24, 2019, 5:01:36 AM

Data source: Data 1 in Figure 5-4_Lerrkocyte adhesion behavior_
WT vs TSG6 null

Failed (P < 0.050)

Normality Test (Shapiro-Wilk)
Group

N

WT Acetone Control
WT Croton Oil
TSG-6 null Acetone Control
TSG-6 null Croton Oil

10
10
11
11

Missing

Median

0
0
0
0

0.000
14.787
0.000
17.647

25%

0.000
4.245
0.000
7.692

75%

4.167
18.904
0.000
25.000

H = 18.951 with 3 degrees of freedom. (P = <0.001)

The differences in the median values among the treatment groups are greater than would be expected by
chance; there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.

All Pairwise Multiple Comparison Procedures (Drum's Method)
Comparison

TSG-6 null Cr vs TSG-6 null Ac
TSG-6 null Cr vs WT Acetone Co
TSG-6 null Cr vs WT Croton Oil
WT Croton Oil vs TSG-6 null Ac
WT Croton Oil vs WT Acetone Co
WT Acetone Co vs TSG-6 null Ac

Diff of Ranks

17.545
14.509
1.509
16.036
13.000
3.036

Q
3.354
2.707
0.282
2.992
2.370
0.566

P<0.05

Yes
Yes
No
Yes
No
No

Note: The multiple comparisons on ranks do not include an adjustment for ties
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